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Abstract 
 
RNA interference (RNAi) has been shown to be highly effective in targeted 
gene knockdown and has the potential to be applied for therapy by silencing 
pathology-causing genes. However, there remain several undesired properties 
associated with the utilisation of RNAi for therapeutic purposes. These include: 
innate immunostimulation, “off-target” cellular sequences and the possibility of 
saturating the endogenous RNAi pathway, which is required for microRNA 
biogenesis. RNA Polymerase III (Pol III) promoters have been used predominantly to 
generate exogenous expressed RNAi precursors. Pol III promoters possess 
constitutive activity in most tissue types and their transcripts can be easily tailored 
into microRNA-like cellular precursor structures. Regulation of Pol III promoters is 
however difficult to achieve, and their lack of tissue specificity and high activity are 
responsible for the toxic saturating effects on the RNAi pathway. In contrast, RNA 
polymerase II promoters express mRNAs which can be regulated and are 
differentially expressed in specific tissues. However, Pol II-transcripts have 
additional sequences such as the 5’ 7-methyl guanosine cap and 3’ polyadenylation 
sequence which make them unsuitable for the generation of important RNAi 
precursors such as short hairpin RNAs (shRNAs). This study aimed to produce a 
series of cytomegalovirus (CMV) promoter-controlled expression cassettes that 
would generate shRNAs lacking unwanted flanking sequences. The precise hairpin 
RNA strand was processed post-transcriptionally through the action of chimaeric cis-
cleaving hammerhead ribozymes that are incorporated up- and down-stream of the 
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shRNA. The hammerhead ribozymes were restored from a minimal state by inserting 
additional extra-core elements allowing for intracellular activity. This design for 
producing active RNAi effector sequences was termed a Ribozyme Processing 
System (RyPS). To evaluate the inhibitory efficacy of RyPS, a previously 
characterised shRNA targeted against the X open reading frame of the hepatitis B 
virus was inserted into a RyPS expression cassette. In vitro co-transcription and 
cleavage experiments demonstrated the processing potential of RyPS. This resulted in 
the formation of 3 products; the upstream and downstream ribozymes and the 
shRNA. Northern blot analysis of in vitro transcription products revealed the shRNA 
and downstream ribozyme were smaller than anticipated. Using primer extension 
analysis the precise ribozyme cleavage sites of the up- and downstream ribozymes 
were mapped. The upstream ribozyme mapped the predicted site, however multiple 
cleavage sites were mapped for the downstream ribozyme. The aberrant cleavage of 
the downstream ribozyme resulted in an shRNA cleaved within the antisense region, 
a sequence which dictates the targeting and inhibitory potential of the shRNA.  
Intracellular transfection of RyPS resulted in little to no inhibition of both live virus 
and targeted reporter genes. It was noted however that the ribozymes maintained 
intracellular activity according to a luciferase-based knockdown assay, in which 
ribozyme activity resulted in luciferase mRNA destruction. By applying these results 
to RNA folding algorithms, a model can be developed where atypical cleavage by the 
flanking ribozymes is avoided, and further allow for the design of more stable RyPS 
and individual ribozyme. Although the current design of the RyPS cassette was 
shown to be ineffective at producing active shRNAs, possible optimisation would 
 vi
involve the substitution of the shRNA, or replacing the chimaeric hammerhead 
ribozyme species with a naturally occurring species. With these changes further 
developments of this post-transcriptional processing system may soon result in 
effective Pol II-generated sequences for therapeutic RNAi. 
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Introduction 
 
Unique new therapeutics against various diseases are often required to be 
developed, particularly when the disease-causing agent develops resistance to the 
existing drugs, or when administration of the drug becomes non-feasible. Drug 
administration to patients is a difficulty in developing countries such as sub-Saharan 
Africa, since travel, storage and patient compliance are many tasks that require 
attention. Ideally potential therapeutic drugs used in these environments would 
require a large degree of stability, relatively easy drug administration and minimal 
patient compliance. One particular therapeutic interest, known as RNA interference 
(RNAi), has gained momentum in the past few years, revealing a system with 
elaborate cellular pathways. RNAi utilizes innate (small processed RNA strands 
produced specifically for RNAi) or exogenous sources of RNA (such as viral RNA) 
to induce the targeted degradation or suppression of a specific RNA strand. From a 
therapeutic perspective these exogenous RNA species can be introduced into a living 
system encoded within various DNA templates such plasmids. This provides cost 
effective and stable therapeutic particles which may provide a solution to drug 
management within developing countries. 
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RNA Interference: The Power of Silence 
 
This highly conserved and homologous pathway within eukaryotes has been 
noted as far back as twenty years ago (Izant and Weintraub 1984; Fire et al. 1991; 
Fire et al. 1998). The molecular mechanism was far from being understood, however 
it was noted that by adding anti-sense RNA to a cell knockdown of a particular 
homologous target was induced. Fourteen years later, Fire and Mello established the 
first basic requirements for the RNAi pathway, and received the Nobel Prize for 
physiology or medicine in 2006 for their contribution and initial elucidation of the 
pathways in RNAi. Their discovery showed that double stranded RNA was far more 
powerful in inducing knockdown than the single anti-sense counterpart within 
Caenorhabditis elegans (Fire et al. 1998). Little did Fire and Mello know, but their 
discovery would lead to the rapid elucidation of multiple RNA processing pathways 
within the cell. Prior to their discovery, anti-sense RNA was thought to induce 
generalized knockdown of all cellular RNA, placing the cell within a “lockdown” 
state, in which little to no transcription takes place (Proud 1995). It was also believed 
that double-stranded RNA is stable enough not to unwind within a cellular 
environment, remaining as a double helix. Fire and Mello’s discovery suggested that 
certain cellular species and pathways are involved in the unwinding of nucleic acids, 
and furthermore, involved in target and effector molecule recognition and binding 
(Mello and Conte Jr 2004). It was shown soon thereafter that if C. elegans was placed 
in an environment containing dsRNA, knockdown would occur of mRNA sequences 
that shared homology with the dsRNA  (Tabara et al. 1998). Furthermore, if C. 
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elegans was fed a diet of bacteria were made to express dsRNA targeting a particular 
gene, knockdown effects were witnessed on that particular homologous target 
(Timmons and Fire 1998; Timmons et al. 2001). So powerful was this effect it was 
seen to be carried over into the progeny of C. elegans within the germ line (Grishok 
et al. 2000). Knockdown studies were soon found to be highly successful in plants 
(post-transcriptional gene silencing, or PTGS), fungi (quelling) and Drosophila 
(RNAi) (Romano and Macino 1992; Fagard et al. 2000; Aravin et al. 2001) .  
MicroRNAs are generated with the nucleus 
 
Innate RNAi plays a vital role in cellular development and maintenance, 
assisting in the regulation of protein and RNA species production within the cell. 
These regulatory events are initiated by small 21-22nt RNA species known as 
microRNAs (miRNAs), which are ubiquitous within cells and over one hundred have 
been classified within the human genome (Lee et al. 2002). MicroRNAs exist in 
unprocessed forms initially and require processing before inducing target knockdown, 
these are termed primary microRNAs or pri-miRNAs (Lee et al. 2002; Bartel 2004). 
Their biogenesis starts in the nucleus, initiated either by a Polymerase II or III 
promoter (Pol II and Pol III respectively). Typically Pol III promoters are highly 
active and induce expression within most cell types, furthermore these promoters are 
involved in the expression of smaller RNA species such as tRNAs, 5S ribosomal 
RNA and U6 snRNA (Bartel 2004). Polymerase II promoters cause the transcription 
of mRNA and certain small RNAs, including the small nucleolar RNAs (snoRNAs) 
and small nuclear RNAs (snRNAs) (Bartel 2004). Several data indicate that Pol II 
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promoters are responsible for generating many of the miRNA species, owing to some 
pri-miRNA species being larger than 1kb and that Pol III is unable to generate such 
large RNA fragments; some pri-miRNAs have been shown to have uridine repeats, 
which would cause transcription termination by Pol III; pri-miRNAs require 
differential expression during development, a feature provided by Pol II, and not by 
Pol III (Bartel 2004; Cai et al. 2004). Other species of miRNAs are found within 
introns of pre-mRNA and are known as mirtrons. These particular species of pri-
miRNAs undergo normal RNA splicing during intron excision and remain as mitron 
lariats before they are debranched and folded into precursor microRNA or pre-
miRNA (Ruby et al. 2007). This form of pre-miRNA generation bypasses any form 
on nuclear endonuclease III processing.  
The pri-miRNA transcript is initially processed by a member of the RNase III 
endonuclease super-family known as Drosha, into a ~60-70nt stem-loop product 
known as  precursor-microRNA or pre-microRNA (Lee et al. 2002; Basyuk et al. 
2003; Lee et al. 2003; Bartel 2004). Drosha does not act alone within the nucleus, and 
forms a complex with several other proteins such as Pasha (partner of Drosha), 
collectively known as the Microprocessor (Denli et al. 2004; Gregory et al. 2004). 
Pasha (known as DGCR8 in mammals) plays and important and interesting role, as it 
is responsible for the stabilisation of Drosha as well binding of the pri-microRNA. 
This occurs because DGCR8 contains two dsRNA binding domains in the C-terminal 
region, both equally responsible for anchoring pri-miRNAs within the 
Microprocessor (Han et al. 2006; Yeom et al. 2006). Also within the C-terminal of 
DGCR8 is the binding and stabilizing domain which interacts with the middle domain 
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of Drosha. The N-terminal domain of DGCR8 contains a nuclear localization signal, 
responsible for the transport of DGCR8 into the nucleus and potentially retaining it 
there (Yeom et al. 2006). 
Drosha cleaves its target pri-miRNA, leaving a phosphorylated 5’ and a 2 
nucleotide 3’ overhang end (Basyuk et al. 2003), producing a pre-miRNA which is 
transported into the cytoplasm. Pre-miRNA transport occurs via the nuclear protein 
Exportin-5, a dsRNA binding protein which is Ran-GTP dependent (Yi et al. 2003; 
Bartel 2004; Bohnsack et al. 2004). The above processes are schematically described 
in Figure 1.1. RNA interference is unable to induce knockdown within the nucleus, as 
multiple protein species and complexes involved in the RNAi pathway are solely 
located within the cytoplasm. This has particular importance as certain viruses 
replicate within the nucleus, thus leaving them unaffected by the RNAi machinery. It 
is required for the target mRNA molecule to enter the cytoplasm, in which it can be 
identified and processed by the RNAi machinery. Use of RNAi against nuclear 
replicating viruses would require combinatorial approaches, in which various 
therapeutic agents are employed, one of which may be ribozymes (catalytic RNA 
molecules) which are able to remain active within the nucleus, cleaving their targets.  
 6
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Figure 1. 1: Generation of Precursor microRNA 
Precursor microRNAs (pre-miRNA) can be generated by two methods, depending on 
their source. A, pre-miRNAs are transcribed from either a Pol II or Pol III promoter, 
to produce either a single pri-miRNA (>80 nucleotides) or a polycistronic pri-
miRNAs containing multiple pri-miRNAs (can be over 1kb). Both forms of pri-
miRNAs are processed by Drosha, within the Microprocessor resulting in a pre-
miRNA product. In the second method, B, pre-miRNAs are derived from spliced 
introns. The intron-pre-miRNAs are known as mirtrons, and require no processing by 
the Microprocessor, but rather debranching to release the conserved adenine from the 
guanine typical of intron lariats, allowing for the pre-miRNA formation. Once either 
pathway has generated a pre-miRNA, it is exported into the cytoplasm via the Ran-
GTP dependent Exportin-5 pathway. 
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Cytoplasmic processing and RISC assembly 
 
The Drosha processed pre-miRNA is exported to the cytoplasm via Exportin-
5, then recognised and bound by Dicer, a cytoplasmic RNase III endonuclease 
(Grishok et al. 2001; Hutvagner et al. 2001). The PAZ (piwi/argonaute/Zwille) 
domain within Dicer contains a binding pocket for the 2 nucleotide 3’ overhang of the 
pre-miRNA and facilitates the binding of the remainder of the pre-miRNA into the 
RNase portion of Dicer (MacRae et al. 2006). Dicer contains two RNase domains, 
each responsible for cleaving one strand of the double helix exactly 25 nucleotides 
from the binding pocket of the PAZ domain. Starting from the 5’end and two helical 
turns towards the loop of the pre-miRNA, Dicer cleaves the dsRNA in a similar 
manner to Drosha producing a 5’ phosphate and a 2 nucleotide 3’ overhang. This 25 
nucleotide distance is facilitated by the connector helix between the RNase and PAZ 
domain, allowing for the exact measurement (MacRae et al. 2006).  
Invasive RNAs, such as those of viral origin, enter the RNAi path at this 
point. Presence of dsRNA is typical of many viral infections. This is also processed 
by Dicer into 21-23 nucleotide fragments, known as small interfering RNAs 
(siRNAs). However without Microprocessor processing, viral RNAs are not as 
efficiently processed as a result of the initial interaction between the 2 nucleotide 3’ 
overhang of the pre-miRNA and the PAZ domain of Dicer (MacRae et al. 2006).  
The final process of the RNAi pathway results in either translational 
suppression or degradation of the target RNA within the cytoplasm. After Dicer has 
cleaved its target, be it innate or exogenously sourced, several proteins are recruited to 
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aid the transfer of the miRNA/siRNA to the RNA induced silencing complex (RISC). 
Two of the important proteins recruited are Argonaute (Ago2 in particular) and TRBP 
(HIV-1 TAR RNA-binding protein) (Lee et al. 2006; Kok et al. 2007; MacRae et al. 
2008). Helicase is also required, as it plays two roles in the process; firstly to unwind 
the double stranded miRNA into its sense and antisense components; and secondly to 
recognize self and non-self RNAs by the presence of the 2 nucleotide 3’ overhang 
(Marques et al. 2006). Both the sense and antisense stands have the potential to be 
incorporated into RISC, however their selection is dependent on the stability of the 5’ 
region. The less stable and easier to unwind strand from the 5’ region is selected and 
incorporated into RISC (Khvorova et al. 2003a; Schwarz et al. 2003; Patzel et al. 
2005).   
The argonaute proteins are a large family of proteins, and at least one is 
present per RISC assembly (Bartel 2004). Like many of the defined proteins 
involved in the RNAi pathway, Ago proteins have domains involved in RNA 
binding, in particular a PAZ domain and a PIWI domain. Both these domains are 
highly conserved, and the PIWI domain containing a fold that resembles RNase-H 
like fold involved in cleavage (Faehnle and Joshua-Tor 2007), however not all 
species of Ago are known to cleave their target. The only Ago species defined thus 
far to cleave its target is Ago2 (Liu et al. 2004). Target RNA cleavage within RISC is 
dependent on features within the guide antisense sequence, and how it associates 
with the target mRNA sequence. Complete and near complementarity between guide 
and target results in mRNA destruction, cleavage occurring ten nucleotides up from 
the 5’ start of the antisense strand. During cleavage the guide strand remains 
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unaffected (Khvorova et al. 2003a; Schwarz et al. 2003; Bartel 2004). Predominately, 
foreign RNA has perfect complementarity, resulting in its destruction. Poor 
complementarity results in translational suppression, in which RISC remains bound 
to the target mRNA strand (Khvorova et al. 2003a; Schwarz et al. 2003; Bartel 
2004).  Translational suppression, amongst other RNAi processes, would seem to 
occur within P-bodies of the cytoplasm, in which no translational machinery are 
present (Liu et al. 2005b; Liu et al. 2005a; Lian et al. 2007).   
 
Silencing the enemy: RNAi and Therapeutics 
 
RNA interference has the ability to induce almost complete knock down of its 
target, making it an extremely potent and specific therapeutic tool. Any disease 
reliant on RNA as an intermediate can be targeted, which ranges from viral infections 
such as Hepatitis B virus and human immunodeficiency virus (HIV), to cancers and 
autosomal genetic diseases. One of the first reported successful treatments against 
disease was shown in 2003, using a mouse model (Song et al. 2003). Since then, 
clinical trials have passed phase 2 against respiratory syncytial virus (RSV) and age-
related macular degeneration (Dykxhoorn and Lieberman 2006).  
Therapeutic molecules can enter the RNAi pathway at multiple stages, by 
either being expressed within the nucleus from an exogenously sourced DNA 
template, or introduced as synthesized RNA, directly into the cytoplasm. It is possible 
to enter the RNAi pathway at multiple stages, in the form of pri-miRNAs, short 
hairpin RNAs or pre-miRNAs, and miRNAs or siRNAs. Other studies have utilized 
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long hairpins, containing multiple siRNAs which rely on Dicer processing 
(Barichievy et al. 2007). Ultimately using synthetic siRNAs to induce target 
knockdown would avoid competition between exogenous and innate pre-miRNAs 
within the nucleus.  This study has chosen to utilize Dicer as the initial stage of 
processing of the RNAi molecules introduced. The main reasons for this are that by 
only using Dicer, nuclear processing can be bypassed, and as Grimm et al. 2006 have 
suggested one can perhaps avoid saturating the nuclear processing component of the 
RNAi pathway. Furthermore, by using the catalytic activities of certain RNA species 
(such as ribozymes) it may be possible to generate a shRNA independent of Pol III 
promoter expression. Currently Pol III promoters are used to generate pre-miRNAs, 
shRNAs and siRNAs owing to their ability to transcribe small RNAs without the 
requirement of large transcription termination sequences; however some of these 
promoters have undesired properties such as high levels of transcription and are 
transcriptionally active in most cell types. Pol II promoters cannot easily be used for 
the generation of siRNAs due to the extra elements produced with mRNA, such as 5’ 
7-methyl guanosine caps and polyadenylated 3’ ends. Should one be able to couple 
tissue specific inducible transcription of a therapeutic molecule, as well as generating 
an exact RNAi effector molecule independent of Microprocessor processing, this 
therapeutically offers a considerable amount of benefit. Benefits include avoidance of 
possible cytotoxic effects produced when saturating the RNAi processing system 
within the nucleus; tissue specific inducible expression, which is energy cost 
effective in cells that do not require treatment.  This project aims to utilise the 
catalytic processing power of ribozymes to generate an active RNAi molecule that 
 12
requires minimal processing, while having tissue specific activity from the Pol II 
promoters.  
Even though one is able to generate an active and effective RNAi therapeutic, 
one field of therapeutics remains challenging and requires a large degree of 
development. The hurdle within this field is delivery of the effector systems, whether 
it be template DNA or synthetic RNA. Current delivery strategies include binding 
moieties such as simple sugars to the RNA molecule, which are exclusively 
recognized by specific tissue type; using an antibody complex with bound RNAs to 
target specific tissue types; encasing the RNA or DNA templates within liposome 
vesicles; using lenti- and adenoviral vectors to convey DNA template to specific cell 
types (Dykxhoorn and Lieberman 2006). 
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Figure 1. 2: Schematic representation of the RNAi pathway within mammalian 
cells. 
Effector RNA sequences are transcribed from the host chromosomal material as pri-
miRNAs, processed and exported via exportin-5 into the nucleus, or alternatively off 
a DNA template as miRNAs, siRNAs or shRNAs. Once in the cytoplasm, the RNA 
duplex is processed by Dicer into ~21-23nt duplex as in path A. The RNA duplex is 
then incorporated into RISC, and induces translational suppression owing to 
mismatches between effector and target sequences. Path B typically involves siRNA 
duplexes inducing target mRNA cleavage once incorporated into RISC. One can 
introduce therapeutic nucleic acids into the RNAi pathway at 3 major points: 1), as a 
pri-miRNA, (transcribed from exogenous sources of DNA such as plasmids) which 
requires processing by the Microprocessor activity; 2) as a shRNA or pre-miRNA 
that only requires nuclear export and Dicer processing and 3) as siRNAs, produced 
individually as sense and anti-sense strands, and forming a duplex within the nucleus. 
Synthetic RNA can also be used to generate siRNAs, which can be introduced into 
the cell via transfection. 
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Resistance development 
 
Like most biological systems, resistance will evolve against drugs and 
therapeutic molecules used to treat disease. Certain viruses have potential to mutate 
easily and become escape mutants, immune to the effects of the therapeutic molecule. 
In particular, in the RNA viruses (single and double stranded) RNA replication relies 
on the RNA-dependent RNA polymerase, which is inherently a poor copier, inserting 
on average 1 mistake every ten thousand bases (Zheng et al. 2005). This would 
theoretically result in escape mutants forming rapidly, depending on viral replication 
rate and mutation rate. Studies done on polio and La Crosse Virus have shown that 
escape mutants can be generated in as little as 72 hours post treatment (Gitlin et al. 
2002; Soldan et al. 2005; Zheng et al. 2005).  
To overcome the chances of creating escape mutants, multi-targeting 
strategies have been employed, often targeting several different sites. Long hairpins 
(Barichievy et al. 2007; Weinberg et al. 2007), interfering multimers (Wilson and 
Richardson 2006) and combinatorial approaches (Li et al. 2006) have been used. An 
interesting combination used by Li et al. 2006, incorporated the use of a siRNA, a 
decoy tat sequestering molecule and a ribozyme. The siRNA was targeted against the 
tat/rev region of HIV mRNA, forming the first form of knockdown. The tat decoy, 
was able to translocate to the nucleus, and bind to Tat proteins, which are required for 
HIV replication, and lastly a ribozyme that targets and cleaves the CCR5 mRNA, 
used by HIV to gain access into host cells (Li et al. 2006). These ribozymes are a 
small species known as hammerhead ribozymes which are catalytically active RNA 
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molecules, naturally involved in cis-cleavage in a multitude of small plant pathogens, 
or as of late involved in therapeutic strategies when cleaving in trans-. This study 
incorporates the cis- cleaving activity of hammerhead ribozymes to generate a 
shRNA molecule. This strategy would be effective, as the ribozymes are independent 
of any processing systems found within the cellular environment, functioning within 
a cellular environment unaided. The following section will elaborate on the 
mechanism of hammerhead ribozyme cleavage, its versatility, diversity and simplicity 
and explaining why these small catalytic molecules are effective and independent 
within a cellular environment, making them ideal therapeutic tools. 
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Hammerhead Ribozyme Mechanism and uses in Therapy 
 
History of discovery 
 
The initial discovery that RNA is both an information carrying molecule as 
well as a catalytic agent was made in the early 1980s by Cech and colleagues, and 
later by Alteman and colleagues (Kruger et al. 1982; Guerrier-Takada et al. 1983).  
The hammerhead ribozyme is one of the smallest known ribozymes, catalyzing the 
nucleolytic transesterification of the phosphodiester backbone, yielding  a 2’3’-cyclic 
phosphate and a 5’ hydroxyl terminus (Prody et al. 1986). Other small species of 
ribozyme include the hairpin ribozyme (Buzayan et al. 1986; Dange et al. 1990), 
hepatitis delta virus (HDV) ribozyme (Wu et al. 1989) and the Neurospora 
mitochondrial Varkud satellite (VS) ribozyme (Saville and Collins 1990). Larger 
species of ribozymes are often involved as part of cellular processes, such as the RNA 
subunit of RNase P (Guerrier-Takada et al. 1983) and introns I and II (Brody and 
Abelson 1985; Sharp 1987). 
The hammerhead ribozyme is the best characterized of the small ribozymes. 
The initial discovery of cis-cleavage by hammerhead ribozymes was within both 
positive and negative strands of viroids and viroid-like satellite sequences (Hutchins 
et al. 1986; Forster and Symons 1987; Daros and Flores 1995). Hammerhead 
ribozymes were also later discovered in caudate amphibians (Epstein and Gall 1987), 
Dolichopoda cave crickets (Rojas et al. 2000), shistosomes (Ferbeyre et al. 1998), 
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and Arabidopsis thaliana (Przybilski et al. 2005). Hammerhead ribozymes derived 
from small plant pathogens have active roles in viral replication, as they are involved 
in separating multimeric genomic concatemers into precursors used in transcription as 
well as replicating the viral genome (Bratty et al. 1993; Symons 1997). Interestingly 
it is suggested that hammerhead ribozymes do not share a common ancestry, and that 
their origins are independent of each other (Salehi-Ashtiani and Szostak 2001).  
  
Mechanism of cleavage: Past theories and current models 
 
The core of the hammerhead ribozyme consists of eleven highly conserved 
nucleotides, created by the junction of three helices, seen in Figure 1.3 (Hertel et al. 
1992) . In several studies the minimal hammerhead ribozyme has been generated in 
various forms as a single strand. Each of the hammerhead species generated differs, 
being defined by the point at which they are connected by their stems and loops. 
Three known variations can occur; by opening stem II and I (Clouet-D'Orval and 
Uhlenbeck 1996); by opening stem II and III (Jeffries and Symons 1989); and by 
opening  stem I and III (Haseloff and Gerlach 1989). These are schematically shown 
in Figure 1.4.  
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Figure 1. 3: Nucleotides within the highly conserved catalytic core of a 
hammerhead ribozyme. 
The numbers accompanying the bases are the international nomenclature used when 
referring to nucleotides within the catalytic core. Stems I, II and III can be made of 
any stable Watson-Crick base pair. The nucleotides in red indicate those involved in 
the conserved catalytic core. The blue nucleotides indicate a target strand, should the 
ribozyme be acting in trans. Within the target sequence is the cleavage triplet NUH, 
where N is any nucleotide and H is any nucleotide but G. The numbering system was 
developed by Hertel et al. 1992, to standardise the data generated from various 
laboratories. The core was labelled in a clockwise manner, and decimal numbers 
indicate the first number of a helix. 
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Figure 1. 4: Three different states in which the minimal hammerhead ribozyme have been artificially constructed. 
In A, helix I and II were left open, and helix III looped. Similarly in B and C, various ends were left open or looped. 
Therapeutically, open helix I and III is the most viable, as most of the catalytic core is contained when the ribozyme is looped at 
helix II. 
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The hammerhead ribozyme undergoes extensive secondary and tertiary 
structure changes to allow for the correct positioning within the catalytic core to 
allow for cleavage (Martick and Scott 2006). Some of these changes involve the 
formation of a three-dimensional γ or ‘wishbone’ structure causing stem II and III to 
co-axially align, and stem I and II to lie adjacent to one another, depicted in Figure 
1.6.  
The core of the hammerhead ribozyme consists of two domains, the first 
comprising of 5’-C3U4G5A6-3’, as well as the H17 residue, typically seen as C17 owing 
to it inducing enhanced cleavage rates. The second domain comprises of 5’-
G12A13A14A15-3’ as well as 5’-G8A9-3’. Although not seen as a domain, the motif 5’-
NU16H17-3’ is of high importance as it makes up the cleavage triplet at which the 
trans-esterification reaction takes place. The 5’-NU16H17-3’ motif can withstand large 
sequence variation, making it ideal for a trans-cleaving therapeutic, cleaving the 
target strand after H17 (Haseloff and Gerlach 1989). 
One flaw in the studies performed on hammerhead ribozymes was the 
removal of extra-core elements, which are often not highly conserved sequences, and 
were overlooked for over 15 years (Uhlenbeck 2003). Removal of these elements 
generated ribozymes known as minimal ribozymes and were considered to have an 
optimal cleavage rate of 1 min-1, under conditions of 10 mM divalent magnesium 
ions, concentrations far higher than in the mammalian cell (Hertel et al. 1994). This 
would seem an ineffective cleavage strategy for plant viruses, as hammerhead 
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ribozymes are known to cleave within cellular environments, and such high 
magnesium concentrations are not found in those particular environments.  
Furthermore, the cleavage mechanism was proving to be elusive as a result of 
the lack of consistent crystallographic data. Two predominating theories were 
accepted as the mechanism of cleavage of the minimal hammerhead ribozyme, both 
incorporating the usage of magnesium ions within the core, effectively creating a 
metalloenzyme. The first theory, known as the single ion theory, proposed that a 
hydroxyl group of a hydrated single divalent metal ion acted as a general base toward 
the 2’ hydroxyl group of the N17 ribose sugar. This caused the 2’ oxygen of the 
hydroxyl group to become a greater nucleophile, resulting in the nucleophilic attack 
on the adjacent phosphate and the generation of a cyclic 2’,3’ phosphate and a 5’ 
hydroxyl group.  This process occurs in the presence of a proton as an electron 
acceptor near the 5’ oxygen (Torres and Bruice 1998; Takagi et al. 2001). The second 
theory, known as the double ion theory, requires that the 2’ hydroxyl of the ribose 
sugar and the 5’ leaving oxygen of N1.1 are both stabilised by a divalent metal ion 
(behaving like Lewis acids), typically magnesium. The stabilisation in turn caused the 
phosphate group to become prone to nucleophilic attack, facilitated by the 2’ 
hydroxyl group. This process occurs without any protons being terminal electron 
acceptors, unlike the first theory. Eventually the divalent metal ions are replaced by 
protons to form hydroxyl groups post cleavage (Lott et al. 1998; Takagi et al. 2001). 
Several other mechanistic theories were generated at the time, however the 
predominantly accepted theories were the single and double divalent metal ion 
mechanism, described in Figure 1.5. 
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Figure 1. 5: The various transitions states of the catalytic region of the 
hammerhead ribozyme, applying the two possible cleavage theories. 
In A, the ribozyme is in a state prior to cleavage initiation. H17 (C17) contains the 2’ 
hydroxyl group which initiates the nucleophilic attack on the scissile phosphate of C1. 
B, demonstrates the single ion mechanism, whereby a hydroxyl group bound to the 
magnesium ion (grey ball) abstracts the hydrogen present on the 2’ hydroxyl group of 
H17. This in turn causes increased instability on the 2’ oxygen and in turn attacks the 
scissile phosphate, resulting in a penta-coordinated state. C demonstrates the double 
ion mechanism, in which similar to the single ion theory, the 2’ oxygen is directly 
abstracted by the magnesium ion, and the 5’ oxygen is treated in a similar fashion. 
This makes the leaving group oxygen of C1.1 more stable, and the nucleophilic attack 
occurs on the scissile phosphate. Panel D shows the ribozyme post-cleavage products, 
a 2’3’ cyclic phosphate and a 5’-OH group. 
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Hammerhead ribozymes were recently re-examined to reassess the cleavage 
kinetics, and it was established that the cleavage rate of “restored” hammerhead 
ribozymes was far greater compared to the minimal species, when the extra-core 
elements were present (De la PenÄ et al. 2003; Khvorova et al. 2003b). The loops of 
stem I and II of cis-cleaving ribozymes were found to undergo non-canonical base 
pairing, resulting in a phenomenon known as a “kissing loop”, which influenced the 
cleavage rate (De la PenÄ et al. 2003; Khvorova et al. 2003b). With these extra-core 
elements present, the reverse ligation reaction is also possible albeit occurring far less 
than the cleavage reaction (Canny et al. 2007). Figure 1.6 demonstrates a potential 
kissing loop interaction within a hammerhead ribozyme, causing the coaxial 
alignment of stems II and III, and the parallel alignment of stems I and II. 
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Figure 1. 6: Difference between the secondary and tertiary structure of a fast-
acting hammerhead ribozyme. 
On the left is the representation of the secondary structure of a hammerhead 
ribozyme. For cleavage to occur a complex tertiary conformation is required, 
stabilised by the kissing loop interaction of the extra core elements (5’-UGGGAU-3’ 
and 5’-UAA-3’) on helix I and II. Helix II and III have aligned co-axially, and helix I 
and II undergoing parallel alignment. 
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In 2006, Martick and Scott produced crystallographic data of the hammerhead 
ribozyme that would change the outlook on the cleavage mechanism. Their data 
showed that the extra-core elements were vital to the formation of the tertiary 
structure required for hammerhead ribozyme cleavage. The “kissing loop” was shown 
to be strong enough to induce partial unwinding of stem I, ultimately leading to an 
intricate set of events within the catalytic core never witnessed before (Blount and 
Uhlenbeck 2005). Some of these events include catalytic core stabilisation by the 
canonical base-pairing of nucleotides G8 and C3; bases such as G12, A13 and A14 
promote conformational locking within the pocket; G5 and A6 wedge themselves 
between C17 and N1.1, forcing catalytic sites closer to each other (Martick and Scott 
2006). This model explains what the minimal model could not, how core bases 
interacted without being over 20 Å apart. Possibly the most important aspect taken 
from this work is that divalent metal ions are not crucial for catalysis, and instead 
play a supportive role in charge neutralization of the phosphate backbone and 
possibly within the catalytic core (Martick and Scott 2006).  Thus instead of metal 
ions, G12 behaves as a general base, abstracting the hydrogen of the 2’ hydroxyl 
group, allowing for the penta-coordinated state to form (Han and Burke 2005; 
Lambert et al. 2006; Martick and Scott 2006). In order to stabilize the 5’-oxygen 
leaving group, G8 behaves as a general acid (Martick and Scott 2006). This reaction is 
depicted in Figure 1.7. These findings make natural hammerhead ribozymes suitable 
therapeutic candidates within an intracellular environment. Their functionality within 
a cellular environment allows for the targeting and cleavage of a particular RNA 
strand, allowing hammerhead ribozymes to be directly involved in cleavage of a 
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target strand, or part of a processing system with aims to release effector therapeutic 
molecules. 
 
 
Figure 1. 7: Penta-coordinated state of a hammerhead ribozyme, proposed by 
Martick and Scott, 2006. 
G12 behaves as a general base, abstracting the hydrogen from the 2’ hydroxyl group. 
G8 behaves like a general acid, stabilizing the 5’ oxygen in the penta-coordinated 
state. These events provide greater stability for the cleavage reaction to occur, in 
which the phosphate will release the 5’ oxygen and produce a 2’3’ cyclic phosphate. 
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One could question whether these extra-core elements are so necessary, since 
minimal hammerhead ribozymes were able to undergo cleavage in vitro. One theory 
is that the very nature of the hammerhead ribozyme is structurally dynamic, and a 
momentary conformation required for cleavage may occur. Another idea is that the 
divalent metal ions are able to play a role in the catalytic reaction, as previously 
proposed (Uhlenbeck 2003; Kisseleva et al. 2005).  
Ribozymes as therapeutic molecules 
 
Minimal trans-cleaving hammerhead ribozymes had low efficacy against their 
targets owing to the poor cleavage ability within a cellular environment. The advent 
of RNAi for therapeutic purposes caused majority of the interest in RNA based 
therapy to be shifted from ribozyme therapeutics. However, since the restoration of 
the natural hammerhead ribozyme, and increased understanding of the cleavage 
mechanism, hammerhead ribozymes have several advantages over RNAi as 
therapeutic molecules. Hammerhead ribozymes are more specific than siRNAs, 
owing to the exact complementarity that is required by the ribozyme catalytic site, 
thus no off targeting can occur (Jackson et al. 2003; Akashi et al. 2005). A side effect 
of using RNAi effector molecules is the risk of inducing immunostimulation 
pathways, such as the interferon pathway, which ribozyme do not (Sledz et al. 2003; 
Judge et al. 2005; Karpala et al. 2005). Furthermore, the innate RNAi pathway is not 
affected by hammerhead ribozymes, avoiding possible toxic side effects seen by 
Grimm et al. 2006. Another advantage is that ribozymes function independently 
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within the cell, and are able to function within the nucleus, an area inaccessible to 
RISC.  
This study did not use the trans-cleaving abilities of the hammerhead 
ribozyme, instead kept it as the more naturally occurring cis-cleavage. Hammerhead 
ribozymes were incorporated into a cleavage-processing system to generate a shRNA 
that does not rely on Drosha and associated proteins for processing. These 
hammerhead ribozymes have the ability to function within a cellular environment at 
physiological concentrations of magnesium, making them ideal processors. 
Furthermore by having these ribozymes in place, it is possible to use tissue specific 
inducible promoters such as the Pol II promoters, which therapeutically is a very 
appealing feature. 
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The Ribozyme Processing System 
 
A ribozyme processing system (RyPS) was constructed in order to generate 
precise Dicer-compatible molecules, driven by tissue specific Pol II promoters. This 
system is unique in its approach, as it allows for several unique features as an RNAi 
therapeutic: RyPS is able to generate a precise Dicer substrate, void of Drosha 
processing. This decreased bio-processing is advantageous as there is a decreased 
chance of creating competition for processing with innate RNAs Grimm et al. 2006; 
The exact Dicer substrate does not require the conventional Pol III promoter 
expression, allowing for inducible, tissue specific, and lower levels of expression. 
Furthermore the RyPS has the potential to be used as a concatemer, generating 
multiple shRNA sequences from a single promoter, preventing promoter exclusion.  
RyPS is composed of one shRNA and two hammerhead ribozymes. The 
hammerhead ribozymes flank either side of the shRNA, their cleavage sites defining 
the start and end of the shRNA. In theory, the hammerhead ribozymes would be 
stable enough to form a cleavage-capable molecule, despite the presence of a strong 
hairpin structure. This system is an improvement of its predecessor, in which 
minimal/slow hammerhead ribozymes were used (Ely, A. 2005 MSc dissertation, 
University of the Witwatersrand). It is now known that these minimal constructs, 
although useful in primary hammerhead structure-function studies, have no 
functioning in mammalian cells owing to the metal ion concentration required for 
cleavage being inadequate. The hammerhead ribozymes currently used in RyPS have 
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the extra-core elements restored within the stems allowing for tertiary structure 
conformational change and increased cleavage rates. This species of hammerhead 
ribozyme does not naturally occur, rather it is a derivative of peach latent mosaic 
virus (PLMV) ribozyme. One change in particular is the addition of the 5’-UAA-3’ 
bulge on stem I. The bulge (5’-UAA-3’) present on stem I originates from a loop 
structure capping the PLMV RNA sequence. This newly incorporated and adapted 
bulge facilitates the interaction of loop II and stem I, allowing for the formation the 
kissing-loop structure.  
Theoretically, the kissing-loop interaction will allow for the RyPS to achieve 
the correct conformation to cleave at the designated sites, releasing the shRNA into 
the nucleus to be translocated by Exportin-5.  A theoretical schematic of the 
secondary structure of RyPS is shown in Figure 1.8. In this diagram one can depict 
the three elements of RyPS, namely the two flanking ribozymes and the shRNA 
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Figure 1. 8: The theoretical secondary structure of RyPS.  
Within the boxes are the PLMV-derived flanking hammerhead ribozymes shown in 
black. The left flanking ribozyme has the stem II and III looped structure, whereas the 
right flanking ribozyme has stem I and II looped.  The ribozyme cleavage site of each 
flanking ribozyme is shown in red, and it should be noted that the left flanking 
ribozyme retains the cleavage triplet 5’-GUC-3’, whereas the right flanking ribozyme 
releases the triplet to be included as part of the 2 nucleotide 3’ overhang of the 
shRNA. Letters shown in blue indicate the bulk of the shRNA. 
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The cleavage products generated may not always be perfect, like any cellular 
species of RNA and protein, mis-folding does occur. The products of an unprocessed 
RyPS cannot enter the RNAi machinery, and will most likely be degraded.  There are 
6 possible species that can result after RyPS processing, the first three and most 
common species will be the released 5’ ribozyme, 3’ ribozyme and shRNA. Other 
minor species present would be a result of mis-folding and include the entire RyPS, a 
conjugated 5’ ribozyme- shRNA and a conjugated 3’ ribozyme-shRNA.  
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Figure 1. 9: Illustration of the possible cleavage products by RyPS. 
The three predominant products are the 5’ ribozyme, shRNA and the 3’ ribozyme 
indicated by the bold arrows. The other three products are an uncleaved RNA 
cassette, a 5’ ribozyme shRNA conjugate and a shRNA 3’ ribozyme conjugate, 
indicated by the faint arrows. 
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As RyPS is intended to act as a therapeutic molecule, testing of it will be done 
in two sections. The first section will deal with the functionality of the hammerhead 
ribozymes, their ability to cleave and produce products in vitro and intracellularly. 
The second section will deal with the ability of the released shRNA to knockdown its 
target effectively. For this a hairpin was chosen that targets a region within the 
hepatitis B virus (HBV) genome that was previously designed by colleagues, and is 
known to be highly effective in inducing knockdown (Carmona et al. 2006).  
The shRNA within RyPS contains an anti-sense sequence targeted against the 
X open reading frame (ORF) of HBV. The X ORF overlaps with two other major 
HBV mRNA sequences, namely the polymerase protein and the surface protein (the 
surface protein composes of three variants) which makes these sequences ideal as 
targets for therapeutic purposes, as not only is the mRNA for the X-protein targeted 
but the mRNA for the polymerase and all 3 surfaces proteins as well. Furthermore, 
this restricts the virus’ ability to mutate easily against the RNAi effector molecule, as 
a single nucleotide change results in over 3 changes in separate viral strands. Figure 
1.10 gives an outline for the genome of the HBV genome, indicating overlapping 
ORFs as well as the target site of the anti-sense sequence of the shRNA. 
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Figure 1. 10: A representation of the HBV genome. 
The centre of the diagram represents the DNA genome, associated. Radiating 
outwards are the core, polymerase, pre S1, pre S2, surface and X ORFs, their start 
indicated by an AUG. The outer shell represents the RNA sequences responsible as 
the transcripts for translation. The Pre C/Pregenome encodes the various core 
proteins, the polymerase protein, and also functions as a template for viral replication. 
The pre S1 encodes one of the S1 protein, involved in the surface of viral particles. 
Similarly, S2 and S encodes for the S2 and surface proteins, involved in the surface 
of the viral particles. The X RNA strand is the smallest of the RNA strands generated, 
and shares sequence homology with all the previously mentioned HBV RNA species. 
The X protein has been allocated a multitude of roles, some of which are not clearly 
defined, however it is known that the X protein plays an important role in viral 
replication. In targeting the X mRNA, viral replication is severely affected, 
furthermore by targeting this region all other viral mRNAs are targeted. The pre 
C/core and S proteins may not be as severely affected by the X-targeting shRNA as 
their ORF lies further upstream. However, the polymerase ORF falls within the 
targeted region and it may also be effectively knockdown. The blue bar across all 
mRNA species indicates the region the shRNA targets against. 
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This study aimed to produce an RNA processing system, capable of 
generating a molecule involved in the knockdown of HBV. Unique in its design and 
function the RyPS provides several advantages over currently used RNAi based 
therapeutics which include: minimal bioprocessing required by the shRNA, which 
avoids disruption of the innate cellular pathways; sensitive, tissue specific and 
inducible expression is possible using Pol II promoters; this product can be encoded 
within a DNA vector, offering several benefits such as stability and the ease of 
packaging into lenti- and adenoviral particles. Although not included in this study, 
ribozymes could be designed to target regions on the HBV genome, providing a 3 
way attack on the target as opposed to one. A single promoter can be used to 
transcribe a battery of RyPS, each encoding a shRNA which targets an individual 
site, helping to curb the generation of escape mutants. RyPS template (DNA) is a 
stable molecule, is easily transported and easily mass produced at source. This is an 
ideal feature for developing countries which cannot support cold-chains for particular 
sensitive drugs with limited shelf lives. 
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Materials and Methods 
 
 
 
Figure 2. 1: General overview of the experimental procedures followed over the 
duration of experimentation. 
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Table 2. 1: Definitions for abbreviations used in materials and methods 
Abbreviation Definition 
RyPS Ribozyme Processing System 
5’Rz Refers to the hammerhead ribozyme upstream the shRNA of 
RyPS 
3’Rz Refers to the hammerhead ribozyme downstream the shRNA of 
RyPS 
∆ Prefix to a ribozyme, indicating a mutational change of that 
particular ribozyme 
Del Deletion within a ribozyme causing its loss of activity 
Trunc Truncation of the ribozyme, decreasing cleavage ability 
pCI- Refers to the CMV promoter-based mammalian expression 
plasmid pCI-neo 
pTZ- 
 
psi-Check2.2 
Refers to a bacterial expression plasmid, pTZ57R, a T/A cloning 
vector 
Refers to the plasmid containing two independently expressed 
luciferase genes, used in knockdown studies 
Rz 
 
An abbreviation for ribozyme used in figures. 
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Generation of RyPS clones 
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Figure 2. 2: A diagrammatic representation of the steps taken to generate 
vectors capable of expressing RyPS within a mammalian cell. 
PCR was used to generate the faster and mutant knockout RyPS clones. Previously, a 
RyPS clone was generated in which a deleterious deletion was present within the 
catalytic pocket of the 5’ ribozyme, rendering it unable to cleave. This 5’ ribozyme 
knockout clone was used as a template in PCR, allowing for the generation of the 
other RyPS species. This was achieved by using primers that would introduce new 
mutations, or reinstate missing bases to restore activity. All required RyPS species 
were generated in this manner, Fast RyPS, 5’ ribozyme knockout mutant, 3’ 
ribozyme knockout mutant and the 5’3’ ribozyme knockout mutant. PCR was 
followed by T/A cloning, in which a single T overhang on the 3’ ends of the PCR 
products are ligated into plasmid vectors (pTZ57R) with single A overhangs. This 
vector has a multiple cloning site which contains several unique restriction sites, 
making the excision of the PCR fragment for further cloning easier. The DNA 
encoding RyPS was excised from pTZ57R and cloned into the mammalian 
expression vector pCI-neo. 
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PCR 
 
pCI-∆5’delRyPS, a mutant RyPS which has lost 5’ ribozyme activity, was 
previously generated and used as a template in PCR reactions to generate RyPS (fully 
functional cassette), ∆3’delRyPS (a non-functional 3’ ribozyme within RyPS), and 
∆5’3’delRyPS (both ribozymes within RyPS were non-functional) fragments. 
Table 2. 2: Primers used to generate required RyPS fragments (and knockout 
clones) by PCR 
Sequence Function 
A) 5’-GATCGCTAGCCACATAACGTC-3’ Generic forward 
primer 
B) 5’-GATCCTCGAGCACATAACGTCGG 
          TGATGA-3’* 
Forward primer to 
restore 5’ ribozyme 
activity 
C) 5’-GATCGTCGACCGGTGGTTTCGTCGCATC-3’ Reverse primer 
D) 5’-GATCGTCGACCGGTGGTTTCGTCGCA 
    TCCCAGC GACTCATC_GGGG-3’# 
Reverse primer to 
generate non-
functional deletion 
* Insertion of T restores 5’ ribozyme activity 
#
 Deletion of A results in the inhibition of 3’ ribozyme activity 
 
One hundred nanograms of template was used in each PCR reaction 
containing 1 mM MgCl2, 0.2 mM dATP, dCTP, dGTP and dTTP, 20 pmol forward 
primer, 20 pmol reverse primer, 10 µl 5x GoTaq Flexi Buffer and 1.25 u GoTaq DNA 
polymerase (Promega, Wisconson USA) in a final volume of 50 µl. Samples were 
initially denatured for 2 minutes at 95oC and then subjected to 30 cycles of 15 
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seconds denaturation at 95oC, 15 seconds of annealing 55oC and 30 seconds 
elongation at 72oC. The final elongation step was 10 minutes at 72oC, ensuring the 
addition of A-overhangs to the fragments. 
The appropriate volume of loading dye was added to each PCR sample and subjected 
to electrophoresis in a boric acid 1.5% agarose gel. The agarose gel contained 0.6 µg 
ethidium bromide per 1 ml of gel, to allow for DNA viewing under UV trans-
illumination. Correctly sized DNA fragments (~216 bp) were purified from the 
agarose using the MinElute Gel Extraction Kit as per instruction provided (Qiagen, 
California USA). 
Plasmid construction and cloning 
 
The purified PCR fragments were ligated into a bacterial expression system, 
pTZ57R/T (Fermentas, Ontario Canada) which contains a multiple cloning site 
(MCS) for simplified cloning. The MCS contains a large variety of single cutting 
restriction sites, providing a fair selection of restriction sites should it be required to 
transfer/clone the fragment into other expression systems. Often for the purposes of 
these experiments, pTZ57R is used as an intermediate, allowing for the transfer of the 
PCR fragment into a mammalian expression system, such as pCI-neo and 
psiCheck2.2. 
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Figure 2. 3: A plasmid map of pTZ57R, used for T/A cloning experiments. 
Some of the unique restriction sites found within the multiple cloning site are shown 
in red. The multiple cloning site (T/A cloning site) is located within the β-
galactosidase gene, and insertion of a fragment into the cloning site would disrupt β-
galactosidase functioning, and if transformed into a β-galactosidase negative bacterial 
strain, prevents the metabolism of X-Gal. Bacterial colonies with the intact β-
galactosidase gene metabolise X-Gal to a blue product, visible to the unaided eye, 
while bacterial colonies containing the DNA sequence of interest remain white. 
pTZ57R also contains an ampicillin resistance gene for selective purposes. 
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The ligation reaction contained 0.054 pmol PCR fragment, 0.18 pmol 
backbone plasmid (with T-overhangs), 3 µl 10x ligation buffer and 5 u T4 DNA 
ligase in a final volume of 30 µl. The ligation was incubated at 16oC for 1 hour with 
agitation every 20 minutes. 
Chemically competent Escherichia coli, strain DH5α, were transformed 
according to the method in Appendix 3 and spread onto Luria Bertani (LB) agar 
plates supplemented with ampicillin, 1.6 mg isopropyl-β-D-thiogalactopyranoside 
(IPTG) and 0.8 mg 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) and 
incubated at 37oC overnight. Single white colonies were picked the following day and 
screened by PCR for insert using the M13 forward and M13 reverse primers, which 
flank the MCS of pTZ57R. 
 
Table 2. 3: Clone screening primers which bind the flanking regions of the MCS 
in pTZ57R 
Sequence Function 
5’-GTAAAACGACGGCCAGTG-3’ Binds the 
M13F site 
5’-CAGGAAACAGCTATGACC-3’ Binds the 
M13R site 
 
Bacterial colonies served as template in each PCR reaction containing 1 mM 
MgCl2, 0.2 mM dATP, dCTP, dGTP and dTTP, 10 pmol forward primer, 10 pmol 
reverse primer, 4 µl 5x GoTaq Flexi Buffer and 0.625 u GoTaq DNA polymerase 
(Promega, Wisconsin USA) in a final volume of 20 µl. Samples were initially lysed 
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and denatured for 2 minutes at 95oC and then subjected to 30 cycles of 15 seconds 
denaturation at 95oC, 15 seconds of annealing 55oC and 30 seconds elongation at 
72oC. The reaction proceeded over 25 cycles. The M13 sites flank the multiple 
cloning site in pTZ57R, M13F 36 bases upstream of the T/A site, and M13R lies 84 
bases downstream of the T/A site. A diagrammatic representation of the MCS of 
pTZ57R can be found in Appendix 1. 
DNA products generated from PCR were subjected to gel electrophoresis and 
viewed under UV trans-illumination. A positive result yielded fragments 377bp in 
size. 
Positive bacterial colonies were inoculated into 10 ml of LB broth, and 
incubated at 37oC overnight. The following day bacterial cells were harvested by 
centrifugation, and plasmids extracted by the alkaline lysis method using the High 
Pure Plasmid Isolation Kit (Roche, Switzerland). The insert was restricted from the 
bacterial expression plasmid (total of 500ng DNA) using 10 u of each XhoI and XbaI, 
Buffer O (50 mM Tris-HCl, 10 mM MgCl2, 100 mM NaCl and 0.1 mg/ml BSA, pH 
7.5) (Fermentas, Ontario Canada) in a total volume of 50 µl for 2 hours at 37oC. The 
restriction digest reaction was subjected to electrophoresis, and DNA fragments 
viewed by UV transillumination once stained with ethidium bromide. The DNA 
fragment was purified from the agarose gel using the MinElute Gel Extraction Kit 
(Qiagen, California, USA). The mammalian expression plasmid, pCI-neo, was 
restricted and purified in a similar manner. This allowed for the generation of 
compatible ends when the plasmid was cleaved with XhoI and XbaI. 
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Figure 2. 4: A plasmid map of pCI-neo. 
The mammalian expression vector, pCI-neo, contains various elements that allow for 
its prokaryotic replication as well as eukaryotic expression. The cytomegalovirus 
(CMV) promoter is used for the expression of products cloned within the multiple 
cloning site of the vector. The vector also contains an intron, expressed by the CMV 
promoter as well as various elements taken from the Simian vacuolating virus 40 
(SV40) such as a polyadenylation signal and a promoter. The vector contains 2 
selectable markers, namely neomycin and ampicillin resistance. Neomycin resistance 
is used in eukaryotic, while ampicillin in prokaryotic cells. The T7 and T3 sites can 
be used for sequencing analyses as well as start sites for in vitro transcriptions. 
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The fragment isolated from the pTZ57R clones was ligated into the previously 
prepared pCI-neo backbone (XbaI and XhoI restriction). Ligation of the restricted 
insert involved 0.054 pmol fragment, 0.18 pmol backbone plasmid, 10 u T4 DNA 
ligase and the respective buffer (Fermentas, Ontario Canada). The reaction proceeded 
at 18oC overnight. The following day DH5α bacteria were transformed with the 
ligation reaction, plated onto ampicillin supplemented LB agar plates and grown at 
37oC overnight. Often it was found that incubation of the bacterial colonies required 
longer than 14-15 hours of incubation, and often 20 hour incubation produced more 
visible colonies. Thus, overnight incubation on plates often refers to 20 hour 
incubations. 
Bacterial colonies were screened by PCR using adapted T7 and T3 primers 
which are larger than the conventional providing greater specificity during screening. 
This method is similar to that used to screen pTZ57R colonies with M13F/R primers. 
The T7 promoter site is 7 bases upstream of the inserted product, and the T3 23 bases 
downstream, producing a positive result in the form of ~280 bases. 
 
Table 2. 4: Adapted T7 and T3 primers used in the PCR screening of positive 
RyPS clones inserted into pCI-neo 
Sequence Function 
5’-GTACTTAATACGACTCACTATAGG-3’ T7 Primer 
5’-AGCATTAACCCTCACTAAAGGG-3’ T3 Primer 
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Bacterial colonies were resuspended as template in each PCR reaction 
containing 1 mM MgCl2, 0.2 mM dATP, dCTP, dGTP and dTTP, 20 pmol forward 
primer, 20 pmol reverse primer, 4 µl 5x GoTaq Flexi Buffer and 1.25 u GoTaq DNA 
polymerase (Promega, Wisconsin USA) in a final volume of 20 µl. Samples were 
initially denatured and lysed for 2 minutes at 95oC and then subjected to 25 cycles of 
15 seconds denaturation at 95oC, 15 seconds of annealing 60oC and 30 seconds 
elongation at 72oC. PCR products were subjected to agarose gel (2%) electrophoresis, 
and DNA fragments viewed by UV trans-illumination. Positive clones were 
sequenced by dye termination sequencing (Inqaba Biotechnologies, South Africa)  
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Generation of the luciferase-RyPS reporter system. 
 
Figure 2. 5: Overview of methodologies to generate the luciferase-RyPS reporter 
system. 
The pCI-neo clones containing the correct respective RyPS clones were used as 
template in a PCR reaction in which new restriction sites were introduced. The PCR 
fragment was inserted into the MCS of pTZ57R by T/A cloning. Screened colonies 
with positive insert were restriction digested with XhoI and NotI and the DNA RyPS 
fragment was ligated into the MCS site psiCheck2.2, which similarly was pre-treated 
with NheI and XhoI. RyPS-encoding DNA indicated by red, luciferase genes 
indicated in orange. 
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Individual functioning of each of the ribozymes with RyPS was tested. It was 
required to have the ribozymes function within RyPS, and not as single entities, as a 
change in surrounding sequences of the ribozymes may have an effect on the 
cleavage activity of each of the ribozymes. The RyPS system was cloned into a dual 
luciferase reporter system. The dual luciferase reporter system contains Firefly and 
Renilla luciferase, each transcribed from individual promoters. In doing so, one can 
target either of the luciferases, inducing their knockdown, while the other expresses 
for background control levels. Both luciferases are encoded within a single plasmid, 
thus providing a very sensitive accurate reporter system. Each of the RyPS clones 
(functional on knockout mutants) were cloned downstream of the coding region of 
Renilla luciferase, thus any ribozyme activity would lead to the disruption of the 
mRNA strand and hence its degradation. By testing each of the knockout mutants, 
activity of the functioning respective ribozyme could be determined. Figure 2.6 gives 
an overall representation of the general mechanism of the Luciferase-RyPS cassettes. 
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Figure 2. 6: Representative figures of the outcomes when the RyPS constructs 
were cloned behind Renilla luciferase. 
Within a cellular environment a non-active cassette, such as the ∆5’∆3’Rz RyPS or 
slow RyPS, would result in functional Renilla luciferase detectable in an assay (A). If 
the ribozyme(s) was active (RyPS, ∆5’ ribozyme knockout or ∆3’ ribozyme knockout 
RyPS), little luciferase activity would be seen (B). In both experiments, Firefly 
luciferase served as a background control. 
 
RyPS encoded sequences within pCI-neo were used as template in the 
following PCR reaction: 100 pg template, 1 mM MgCl2, 0.2 mM dATP, dCTP, dGTP 
and dTTP, 20 pmol forward primer, 20 pmol reverse primer, 4 µl 5x GoTaq Flexi 
Buffer and 1.25 u GoTaq DNA polymerase (Promega, Wisconsin USA) in a final 
volume of 20 µl. PCR samples were initially denatured for 2 minutes at 95oC and 
then subjected to 30 cycles of 15 seconds denaturation at 95oC, 15 seconds of 
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annealing 55oC and 30 seconds elongation at 72oC. The final elongation step was 10 
minutes at 72oC.  
 
Table 2. 5: Primers used to generate RyPS fragments from PCR containing the 
correct restriction sites for cloning into psi-Check2.2 
Sequence  Function 
A) 5’-GATCCTCGAGCACATAACGTCG-3’ Forward primer 
to generate 
“faster” RyPS 
B) 5’-GATCGCGGCCGCCGGTGGTTTCGTCGCATC-3’ Reverse primer 
to generate 
“faster” RyPS 
C) 5’-GATCCTCGAGTCTAGACGCCTGATGAGTC-3’ Forward primer 
to generate 
original/ 
slow RyPS 
D) 5’-GATCGCGGCCGCACTAGTTGCTTTGAGGCACT-
3’ 
Reverse primer 
to generate 
original/ slow 
RyPS 
 
PCR products were subjected to electrophoresis and stained with ethidium 
bromide. Fragments were purified from the agarose gel and ligated into pTZ57R, 
transformed into DH5α cells and screened by M13F/R PCR, as previously 
performed.  
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The positive RyPS clones, now containing modified restriction sites for 
insertion into psiCheck2.2, were treated with XhoI and NotI (Fermentas, Ontario 
Canada) in the following reaction: 1 µg template DNA, 5 µl buffer O, 10u of each 
restriction enzyme in a total volume of 50 µl, incubated at 37oC for 2 hours. 
Similarly, linearised psiCheck2.2 backbone was prepared this way. Ligation of the 
restricted insert involved 0.054 pmol fragment, 0.18 pmol backbone plasmid, 10 u T4 
DNA ligase and the respective buffer. The reaction proceeded at 18oC overnight. The 
following day DH5α cells were transformed with the ligation reaction, plated onto 
ampicillin supplemented LB agar plates and grown at 37oC overnight. 
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Figure 2. 7: Plasmid map of psiCheck2.2. 
Renilla luciferase expression is transcribed by a SV40 promoter. Downstream of the 
Renilla gene is the multiple cloning site, often used for insertion of target sequence in 
knockdown studies. Firefly luciferase is used as a background control when Renilla is 
knocked down, and is transcribed by a Herpes Simplex Virus (HSV) promoter. The 
plasmid also contains an ampicillin resistance gene (AmpR), used for bacterial 
selection and culture. 
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DNA preparation for general use and transfection. 
Clones were picked and grown in 3 ml LB broth at 37oC with shaking for 8 
hours. This culture was used to inoculate 50 ml LB broth for DNA used in cloning 
experiments or 200ml LB broth for transfections. Both were grown at 37oC overnight 
with shaking. Bacterial cells were harvested by centrifugation, at 4000xg for 20 and 
35 minutes for the 50 ml and 200 ml cultures respectively. Supernatant was discarded 
and the bacterial pellets were treated with the Hispeed plasmid midi kit or EndoFree 
plasmid maxi kit supplied by Qiagen according to manufacturer’s instructions. This 
preparation relies on the alkaline lysis of bacterial cells in which a sudden pH change 
causes the precipitation of the non-plasmid bacterial components such as 
chromosomal DNA and cellular proteins. 
 
In vitro transcriptions 
Template Generation 
 
PCR was used to generate template for in vitro transcription. The T7 
(forward) primer and a respective reverse primer was used in the following PCR 
reaction containing 100 ng of template, 1 mM MgCl2, 0.2 mM dATP, dCTP, dGTP 
and dTTP, 20 pmol forward primer, 20 pmol reverse primer, 10 µl 5x GoTaq Flexi 
Buffer and 1.25 u GoTaq DNA polymerase (Promega) in a final volume of 50 µl. 
Initially samples were denatured for 2 minutes at 95oC, and then subjected to 30 
cycles of: 95oC for 30 seconds, 55oC for 15 seconds and 72oC for 15 seconds. DNA 
fragments were purified from an agarose gel post electrophoresis as mentioned 
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previously. Alternatively, template was generated by restriction digest. Each 
respective (pCI-neo clone) clone was treated for 2 hours by BglII and XbaI in 2x 
Buffer Tango (66 mM Tris-acetate, 20 mM Mg-acetate, 132 mM K-acetate and 0,2 
mg/ml BSA, pH 7.9) at 37oC. This generates a fragment that contains the upstream 
T7 promoter site as well as an extended 3’Rz. Restriction fragments were purified by 
electrophoresis and gel elution, as mentioned previously. 
 
 
Figure 2. 8: Schematic representation of the DNA templates used in the in vitro 
transcription reactions. 
Shown in green are the DNA templates of the flanking ribozymes, in orange the 
shRNA. The T7 promoter binding site is shown in yellow, and the arrow denotes the 
transcription start site. Light blue regions indicate DNA belonging to the backbone of 
pCI-neo. 
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Having these two templates allowed for various factors to be incorporated. 
PCR generated template provides the exact template for RyPS to be produced which 
includes the T7 binding site. This method causes the 5’ and 3’ ribozyme RyPS 
products to be similarly sized, which may cause difficulty in identification of bands 
species in further analysis. However the advantage to this is that an exactly RyPS 
system is produced without flanking sequences which may interfere with processing 
or folding. Generating template by restriction digest results in a larger 3’ ribozyme, 
which is easier to distinguish from the 5’.  
In vitro transcription 
 
The in vitro transcription reaction comprised of 350 ng DNA template, 20 µCi 
[α-32P]ATP and the required components from MEGAshortscript™ high yield 
transcription kit (Ambion, California USA). The reaction was performed at 37oC for 
2 hours. An equal volume of loading dye was added to the transcription reaction and 
samples placed on ice. Two microlitres were loaded on a 41 cm denaturing 
polyacrylamide gel (Appendix 1). Electrophoresis was performed at 1500 V and 30 
mA for 5 hours in 1x TBE buffer. An X-ray film was exposed to the gel for 15 
minutes in a cassette at -70oC and developed.  
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Tissue culture, transfections and RNA collection 
 
Two cell lines were involved in the experiments performed, namely Human 
embryonic kidney cells (Hek293) and Human hepatocytes (Huh7). Hek293 were 
found to grow in culture more easily and consequently were used in experiments 
which did not require any hepatitis B virus products.  
Cell culture 
 
Cells lines were cultured in Dulbecco/Vogt Modified Eagle's Minimal 
Essential Medium (DMEM) containing 10% foetal calf serum (FCS), and kept at 
37oC and 5% CO2. Once cells reached 90-100% confluency they were split to 30% 
confluency, by removing any media with a phosphate-buffered saline (PBS) wash, 
and then adding an equal volume (as the media) of PBS to the cells and incubating at 
37oC for 5 minutes. The PBS was then removed and one tenth of that volume 
replaced with DMEM. Hek293 cells at this point were easily removed off the surface 
of the dish. Huh7 cells however, are treated with 3.5 mg trypsin per 10 cm2 dish for 5 
minutes at 37oC in place of the second PBS wash used for Hek293 cells, and then 
removed from the culture dish surface in a similar fashion. Cells were counted using a 
haemocytometer where necessary. 
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Figure 2. 9: Basic overview of the experiments involved in the cellular 
assessment of RyPS. 
Each experiment was separately performed, post transfection. Cells turn green owing 
to GFP being present within the transfection mix, a control step to ensure transfection 
was effective. 
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Transfections 
 
All transfections were carried out in wells with a 2cm diameter (typically a 24 
well dish), unless otherwise stated. Per well, 1 µg of DNA was added to 50 µl of 
optiMEM (Invitrogen, California USA), and incubated for 5 minutes as well as 1 µl 
of lipofectamine (Invitrogen, California USA) was added to 50 µl of optiMEM and 
incubated for 5 minutes. Both DNA and lipofectamine mixes were combined, 
thoroughly mixed and incubated for a further 20 minutes in the dark. This was then 
added to the cells and incubated at 37oC, 5% CO2 for 5 hours, after which the 
medium was removed and replaced with fresh DMEM supplemented with 10% FCS. 
Cells were left for 48 hours post transfection without a change of media, and 
necessary components harvested. 
ELISA against HBsAg 
 
An ELISA was performed against the HBsAg of hepatitis B virus. This assay 
allows for the detection the viral production within a cell, as the S proteins are shed 
from the cells into the media, or sera. To measure viral replication, an ELISA against 
the E antigen would be more fitting, as this protein appears when viral transcripts are 
produced. It is necessary to use Huh7 cells for this experiment, as HBV does not 
replicate in Hek293 cells. 
Forty eight hours post transfection, supernatant was removed from Huh7 cells 
(stored at -20oC if necessary) for an antiHBsAg ELISA, using the Monolisa Ag HBs 
Plus kit (Bio-Rad, California USA). The assay relies on a “sandwich” based 
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approach, whereby the detection monoclonal antibodies are bound to a peroxidase. 
This assay is colorimetric in nature, and final results are measured at 450 and 650 nm. 
For a full protocol, refer to Bio-Rad Monolisa Ag HBs Plus kit protocol. 
 
Dual luciferase based assay 
 
The luciferase assay is a more sensitive assay compared to the ELISA. This 
increased sensitivity is for several reasons, including that data do not rely on the 
uniformity of cells per dish, usage of a background control encoded on the same 
plasmid as the target molecule and optical sensitivity of the system is greater. A 
region downstream of Renilla luciferase mRNA is targeted, resulting in its 
knockdown, while Firefly luciferase provides a comparable background. 
The supernatant was removed from Hek293 cells and discarded. No washing 
was done to remove the minor amount of supernatant left, as cells may lift from the 
plate surface. Cells were then incubated with 100 µl 1x Passive lysis buffer 
(Promega, Wisconsin USA) for 20 minutes at 37oC, with no shaking. Cell lysate was 
thoroughly mixed until homogeneous. Ten microlitres of each sample was aliquotted 
into a plate specifically designed for fluorescence-based optical readings (Promega, 
Wisconsin USA). In sequential order, 50 µl of luciferase assay reagent II (LARII) 
was added (contains Firefly luciferase substrate), and a fluorescence measured with a 
green trace, 50 µl of Stop and Glo (which contains Renilla luciferase substrate and 
Firefly luciferase quenching agents) was added and fluorescence measured with a 
blue trace (This protocol has been modified from the original Dual-Luciferase 
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Reported Assay System from Promega, California USA). In this experiment, Renilla 
luciferase mRNA was knocked down, thus the Firefly luciferase served as a 
background control. It is also possible to knockdown Firefly luciferase mRNA, 
however Renilla would then have to serve as a background control. 
 
Northern blots and associated procedures 
 
The northern blot is a sensitive assay in which RNA can be detected using 
either a DNA or RNA probe. Sensitivity can be controlled by the stringency steps 
used to remove incorrectly bound probe. Furthermore, radioactively labelled probes 
provide a large degree of sensitivity in the detection of minuscule amount of RNA.  
RNA extractions 
 
Huh7 cells were cultured using methods mentioned previously under cell 
culture, however, a 10 cm culture dish was used. (Transfections were based on the 
same ratio of cells:DNA. Thus the amount of DNA used per transfection scales with 
the amount of cells present per dish.) Forty eight hours post transfection, supernatant 
was removed and cellular content was harvested by adding 1 ml Tri-Reagent (Sigma), 
incubating for 5 minutes at room temperature. Cell lysate was collected and 200 µl 
chloroform added, which was gently vortexed briefly and left to stand at room 
temperature for 15 minutes. Samples were subjected to centrifugation at 12,000xg for 
15 minutes at 4oC. The upper clear phase contained RNA, and was separated from the 
sample and to this 500 µl isopropanol was added. Samples were left at room 
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temperature for 15 minutes and then subjected to centrifugation at 12,000xg for 10 
minutes at 4oC. Supernatant was discarded and the RNA pellet washed in 1ml 75% 
ethanol and centrifuged for 10 minutes at 7,500xg 4oC. RNA pellets were air dried for 
10 minutes and resuspended in 100 µl TE buffer (10 mM Tris, 1 mM EDTA pH 8). 
RNA samples were immediately stored at -20oC. It is important to note that all 
reagents used as well as procedures performed should be as RNase-free as possible. It 
can be achieved by treating instruments such as spatulas with 1% SDS solution, and 
then autoclaving afterward. DEPC treated water (Appendix 2) was used to make all 
solutions such as buffers. Reagents used were certified to be of analytical grade, and 
were kept separate from those used in general lab usage. 
Electrophoresis 
 
A 20 cm 12% denaturing polyacrylamide gel was loaded with 30 µg of each 
respective RNA sample (RNA was premixed with a DNA/RNA loading dye). 
Electrophoresis was performed in 0.5x TBE buffer at 350 V and 30 mA for 5 hours, 
or until the bromophenol blue band reaches the bottom of the gel. The gel, filter paper 
and nylon membrane (Hybond N) were all cut to the size of the area in which the 
RNA had migrated within the gel. A sandwich setup was created where by the gel 
was placed on moistened membrane, and then three layers of moistened filter paper 
were placed on both sides (0.5x TBE was used to moisten). 
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Blotting 
 
Semi-dry electrophoresis was carried out at 300 mA (3.3 mA/cm2) for 30 
minutes. The membrane was removed and dried at room temperature, after which the 
RNA was UV cross-linked for 1000 µJ over a period of 1 minute and then baked at 
80oC for 30 minutes.  
 
Hybridisation and oligonucleotide preparation 
 
Oligonucleotide probe preparation 
 
End-labelled DNA probe was prepared by using 10 u T4 polynucleotide 
kinase (Fermentas, Ontario Canada), 1 µl 10x T4 polynucleotide kinase buffer, 20 
µCi [γ-32P]ATP (3000 Ci/mmol), 10 pmol DNA oligonucleotide in a final volume of 
10 ml, incubated for 30 minutes at 37oC. Probe oligonucleotides were purified in a 
Sephadex G-25 column.  
Hybridisation 
 
Membranes were prehybridised with 25 ml Rapid-Hyb buffer (Amersham, 
New Jersey USA) for 30 minutes at 42oC (0.25 ml/cm2).  Labelled probe was added 
to the hybridisation buffer after the prehybrisation step. 
Hybridisation was then allowed to proceed for one hour at 42oC. The 
hybridisation buffer was discarded, and the blot washed with the non-stringent 5x 
SSC 0.1% SDS solution for 20 minutes at room temperature. Wash solutions were 
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discarded and blot dried at room temperature. X-ray film was exposed to the blot 
overnight at -70oC. 
 
Cleavage site determination by primer extension reactions 
 
Primer extension reactions provide information to determine where the 
template (target) starts (from the 5’ end). This is accomplished by having a primer 
bound downstream undergo a polymerase reaction (either by reverse transcriptase for 
RNA or Taq polymerase for DNA). In this case, reverse transcriptase and a DNA 
probe were used to determine at what point the products produced by RyPS cleavage 
start. The 3’ ribozyme (thus the 3’ ribozyme cleavage site) was probed and the 
shRNA (thus where the 5’ ribozyme cleaves). If used in conjunction with a marker 
ladder size increases can easily be distinguished. This experiment utilized a 
sequencing reaction as a ladder, using similar probes as in the primer extension. In 
doing this, not only can the size difference be noted, exact site of cleavage can also be 
mapped. 
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Figure 2. 10: 
Overview of the 
primer extension 
reaction used to 
determine the 
cleavage sites of 
each of the 
ribozymes in 
RyPS. 
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Primer extension 
 
The adapted T7 primer and a reverse primer were used in the following PCR 
reaction containing 100 ng of template, 1 mM MgCl2, 0.2 mM dATP, dCTP, dGTP 
and dTTP, 20 pmol forward primer, 20 pmol reverse primer, 10 µl 5x GoTaq Flexi 
Buffer and 1.25 u GoTaq DNA polymerase (Promega) in a final volume of 50 µl. 
PCR conditions as follows; 2 minutes at 95oC, 30 cycles of: 95oC for 30 seconds, 
55oC for 15 seconds and 72oC for 15 seconds. DNA fragments were purified from an 
agarose gel post electrophoresis as mentioned previously.  
The MEGAshortscript™ high yield transcription kit was used for the in vitro 
transcription reaction and contained 350 ng DNA template. The reaction was carried 
out at 37oC for 1 hour. Samples were stored at -20oC directly after incubation until 
use.  
End labelled probe used in the reverse transcription reaction was generated in a 
similar manner used for the northern blots. 
RNA template generated from the in vitro transcription was used in a reverse 
transcription reaction. The protocol followed was as per stipulation in the 
Sensiscript® Reverse Transcription Handbook from Qiagen. 
 
Sequencing-size determination reaction 
 
Sequencing was performed using the same oligoprobes in the reverse 
transcription kit. This would allow for a direct correlation between the size of the 
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primer extended product and relevant positioning in the sequencing reaction, thus one 
would be able to determine exact position of ribozyme cleavage. The CycleReaderTM 
DNA sequencing kit from Fermentas was used and 150 fmol of DNA template in the 
form of whole plasmid (pCI-neo clones) used in the reaction. Both reactions were 
stopped by the addition of an equal volume of DNA/RNA loading dye.  
Five microlitres of each reaction (primer extension and sequencing) was 
loaded into a 41cm denaturing 10% polyacrylamide gel and was subjected to 
electrophoresis at 1500 V 30 mA. An X-ray film was exposed to the migrated 
products overnight at -70oC and autoradiography performed. 
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Results and Discussion 
 
In vitro Transcriptions 
 
Initially it was necessary to determine whether RyPS was able to function in 
an environment optimal for ribozyme activity. The RyPS predecessor showed some 
activity within the in vitro environment, using minimal hammerhead ribozymes. Thus 
it was assumed that a greater rate of cleavage was obtainable by the faster 
hammerhead ribozymes. This activity is thought to be due to concentration of 
divalent cations, which within the in vitro environment is often far higher than is 
required by hammerhead ribozymes for cleavage, thus within this environment results 
obtained represent products from RyPS cleavage, and not whether RyPS is viable in 
cellular environments. The surplus of magnesium ions present within the buffers (6 
mM) allows for cleavage to take place, irrespective of the hammerhead ribozyme 
being minimal form. Ideally 3 major cleavage products would result from RyPS 
cleavage, namely the 5’ and 3’ ribozymes, and the shRNA. The other products that 
would be expected are caused by malformation of any structures within RyPS, 
preventing cleavage, however these species would be present in far smaller amounts 
compared to the main cleavage products. Figure 3.1 demonstrates the possible 
products generated by RyPS. 
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Figure 3. 1: Illustration of the possible products formed by the faster RyPS 
during in vitro transcriptions. 
The RyPS products indicated by the bold arrows are the major products, whereas 
those by the thin arrows are the minor products. Any of the knockout RyPS species, 
would produce products indicated by the thin arrows, and would be a predominant 
species in that particular reaction. 
 
Producing the RyPS within an in vitro environment would be the first step in 
visualizing the potential cleavage products. The environment of the reaction (which is 
dependent on the conditions which would suit the bacteriophage T7 polymerase for 
peak activity) has a high concentration of magnesium ions, far higher that would be 
found in any cellular environment. Using this environment, the rate limiting factor is 
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not the presence of divalent magnesium, and both minimal and fast ribozymes will 
function fully.  
Initially DNA template for the in vitro transcription was generated by 
restriction digests of the respective plasmids. Depending on the restriction enzyme 
used, one could control the length of template downstream of RyPS, thus the larger 
the end length, the larger the 3’ ribozyme would be after cleavage. It is assumed that 
owing to the degree of secondary structure present within the ribozyme, the extra 
downstream sequence generated from downstream restriction sites will not interfere 
with the 3’ ribozyme cleavage reaction. SalI was used to cleave downstream of the 3’ 
ribozyme. However it was speculated that because it is not a blunt cutting enzyme 
may give rise to additional products of different sizes in the transcription reaction 
owing to premature release of the polymerase from the template, which may vary 
from 1-2 bases in size. This size variation of the 3’ ribozyme was found to occur (data 
not shown), and template was therefore generated by the blunt-cutting SmaI digest. 
This caused the 3’ ribozyme to be slightly larger (7 bases) however predictive RNA 
folding analysis showed that the secondary structure of the hammerhead was not 
affected (data not shown). Tabulated in Table 3.1 are the sizes of expected RyPS 
products from template generated by a BglII and SmaI digest. 
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Table 3. 1: Potential RyPS products and their predicted sizes to be generated by 
cis-cleavage after an in vitro transcription reaction using template generated by 
restriction digest 
 
     Product 5’Rz 
(nt) 
3’Rz 
(nt) 
Hairpin 
(nt) 
5’Rz-
hairpin 
(nt) 
Hairpin-
3’Rz (nt) 
RyPS 
(nt) 
Minimal 
System 
71 62 69 140 131 202 
Fast System 75 88 69 144 157 232 
∆5’Rz 
Knockout 
Absent  88 Absent 144 157 231 
∆3’Rz 
Knockout 
75 Absent Absent 144 157 231 
∆5’∆3’ 
Knockout 
Absent Absent Absent Absent Absent 230 
 
 
The RNA produced from the in vitro transcriptions was radio-labelled, and 
separated in an acrylamide based gel by electrophoresis. The gel was exposed to X-
ray film, and the RNA products from RyPS cleavage was visualized as bands. It was 
found that irrespective of the nature of the 3’ end of the template (overhanging or 
blunt) multiple bands would still form from the 3’ ribozyme ranging in 1-2 bases. 
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Cloning generated a truncated 5’ ribozyme and served as a useful control 
element in size determination and comparison to other RyPS RNA species present. 
The truncated 5’ ribozyme is 11 bases smaller than the normal, thus making it 64 
bases pairs in size. This truncation results in the removal of the bulge (5’-UAA-3’) 
from stem I, essentially rendering the fast hammerhead to a structure similar to that of 
a minimal hammerhead ribozyme, unable to form sustained tertiary structures during 
cleavage. Without the presence of either loop II or bulge on stem I, the tertiary 
structure required for cleavage would only occur when there is a correct momentary 
conformational change. The structural differences of the three 5’ ribozymes (fast, 
minimal and truncated), are compared Figure 3.2.  
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Figure 3. 2: Diagrammatic comparison of the various hammerhead ribozymes 
included within the RyPS species. 
The catalytic core of the hammerhead ribozyme does not change, and is constant in 
each of the ribozyme species. In A, the minimal ribozyme is smaller than the faster 
counterpart, these differences accounted for the decreased size of stem I (5’-UAA-3’ 
bulge), stem II as well as loop II. B includes the bulge and loop structures involved in 
tertiary stabilization. The truncated ribozyme C, only has one adenosine from the 
stem I bulge remaining and cannot participate in tertiary structure formation. 
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An in vitro transcription of 4 of the clones, slow RyPS, fast RyPS, ∆5’Rz 
RyPS and truncated 5’Rz RyPS, showed that the RyPS was highly efficient in its cis-
cleavage, producing almost all product and very little initial substrate. The three 
predominant products can be seen in Figure 3.3, in descending order of 3’ ribozyme, 
5’ ribozyme and then shRNA. The slow RyPS underwent poor cleavage of the 3’ 
ribozyme, as most of the shRNA and the 3’ ribozyme remain bound together which is 
postulated to occur because of the different cleavage triplet (5’-CUC-3’) encoded 
within the 3’ slow ribozyme. It is known that the triplet NUH is a universal cleavage 
triplet for hammerhead ribozymes, however certain triplets have shown improved 
cleavage.  
∆5’Rz RyPS clone does not allow for any cleavage activity within the 5’ 
ribozyme, owing to the deletion of the highly conserved uracil group within the 
ribozyme catalytic pocket. The uracil is part of the motif 5’-C3U4G5A6-3’ which plays 
a pivotal role in the formation of the tertiary structure of the hammerhead ribozyme. 
This motif undergoes an 180o internal rotation to facilitate the tertiary structure 
formation, and consequently removal of any of the four nucleotides would result in a 
loss of ribozyme flexibility, hence loss of activity. Interestingly it has been found, 
that when that particular uracil in the 5’-C3U4G5A6-3’ motif is substituted with a 
cytosine to 5’-C3C4G5A6-3’, the ribozyme still maintains activity (data not shown). 
This activity is expected because of the presence of the pyrimidine base found within 
both cytosine and uracil. 
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∆5’Rz RyPS has an inactive 5’ ribozyme thus only the 3’ ribozyme and the 
conjugated 5’ ribozyme-shRNA will be present as cleavage products after in vitro 
transcription. This allowed for the deductive identification of the band species present 
on the X-ray film produced by in vitro transcription. Furthermore, this data was 
supported by the positioning by the truncated 5’ ribozyme, confirming the identities 
of all the band species. In Figure 3.3, all the band species can be identified, clearly 
showing the potential of ribozyme cleavage activity within an in vitro environment. 
RyPS functions well within an in vitro environment, as shown in previous 
studies using the minimal hammerhead ribozymes (unpublished data), and is 
postulated to occur because of the magnesium ion content. However, if the postulated 
cleavage and conformation mechanism by Martick and Scott 2006 is valid, then the 
high magnesium ion concentration will have little to do with the outcome of the 
cleavage reaction. Instead, the metal ions function to bind to the negatively charged 
phosphodiester backbone of RNA, causing an overall decrease in the negative charge 
of the backbone, and thus increased overall stability of secondary and tertiary 
structures. Previously it was thought that the magnesium ions play a direct role in 
cleavage reaction, and depending on their role would act as general acids or bases, 
similar to the functional groups found within the catalytic pocket of a hammerhead 
ribozyme. The minimal hammerhead ribozyme system had no other means to initiate 
cleavage other than using metal ions as catalysts and randomly instantaneous 
cleavage conformation, owing to the lack of extra-core elements. It would not be 
impossible for the metal ion-initiated cleavage theories to apply to the fast acting 
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hammerhead ribozymes in which magnesium ions enter the catalytic pocket and 
become involved in the cleavage reaction. This would seem to be the case for the 
slow RyPS, even though it is unable to sustain a tertiary structure responsible for 
cleavage, as it is still able to cleave within an in vitro environment. It is possible that 
ribozyme cleavage could occur via both mechanisms, by which metal ions as well as 
core elements help facilitate the cleavage reaction while extra-core elements provide 
stability for tertiary structure and align required groups for cleavage. The cleavage 
reaction of the slow RyPS (Figure 3.3 in results) during in vitro transcription shows 
that the 3’ ribozyme undergoes very poor cleavage and is thought to occur because of 
the cleavage triplet used. It has been shown that NUH is the best general formula for 
the cleavage triplet, and has been extended to NHH which is far more 
accommodating for target cleavage sites or triplets however is known to be less 
effective for cleavage, resulting in slower cleavage. The best rate of hammerhead 
ribozyme cleavage has been found using the 5’-GUC-3’ cleavage triplet, and the slow 
minimal RyPS used the triplet code is 5’-CUC-3’ in the 3’ ribozyme, which most 
likely accounts for the poor cleavage seen from in vitro transcriptions. One may 
attribute the decrease in cleavage to the change from a purine to a pyrimidine base, 
and as Martick and Scott 2006 indicate, special arrangement within the catalytic 
pocket of the ribozyme plays an important role in cleavage. It would appear that even 
though not highly conserved, the cleavage triplet sequences play an important role in 
rate of cleavage, and I suspect that it is owing to overall stem III stability in keeping 
the tertiary structure more stable during cleavage.  
 83
 
 
 
 
 
 
 
 84
Figure 3. 3: An autoradiograph of in vitro transcription products subjected to 
electrophoresis in a 10% denaturing polyacrylamide gel. 
Lanes A-B contain size markers, of 116 and 35 nt respectively. Lane C contains the 
RyPS system containing the minimal/slow ribozymes. On the left of the diagram, the 
two products produced by the minimal system are indicated. Lane D contains the 
functional faster RyPS, and lanes E-F contain faster ribozymes modified such that 
they are either non- or less functional. Lane E contains the 5’ ribozyme knockout 
clone whereby the 5’ ribozyme does not cleave, and F a truncated version of the 5’ 
ribozyme, essentially functioning as a minimal ribozyme. On the right of the diagram, 
the knockout 5’ ribozyme + shRNA product is indicated, below that all the other 
products produced by RyPS. The lowest label is the truncated 5’ ribozyme, which is 
seen below the shRNA. Even though truncated, the 5’ ribozyme is still functional. 
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A second autoradiograph was produced using PCR product as template for the 
in vitro transcription, as opposed to a template generated by restriction digest as 
before. When using PCR product as template, the size of the 3’ ribozyme decreases 
because no additional downstream sequences are present, previously generated by 
restriction digestion. The following experiment contained additional controls, in the 
form of a 3’ ribozyme knockout (∆3’Rz RyPS) and a 5’ and 3’ ribozyme knockout 
(∆5’∆3’Rz RyPS). These two controls would provide confirmation of the species 
seen on the previous autoradiograph. Additionally, by changing the forward primers 
used to generate the template, one could modify the 5’ ribozyme to be a different size 
from the original species. This was done by including 5 additional non-interfering 
bases to the forward primer. This would result in a template that after in vitro 
transcription, produces 5’ ribozyme that has 5 additional bases. Template sizes 
generated by PCR and restriction digest have been compared in Figure 3.4. 
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Figure 3. 4: Templates used for in vitro transcriptions. 
In B-E the template comprises of the CMV promoter, an intron and extra nucleotides 
from the backbone, resulting in a fragment ~1350bp is size. This fragment is 
generated by a BglII/SmaI digest on the RyPS clones within pCI-neo. In G-K, the 
templates are generated by a PCR reaction and are far smaller than the previous 
template used. These fragments are approximately 210 bp is size.  A) DNA size 
marker, B) slow/minimal RyPS template, C) RyPS template, D) ∆5’Rz RyPS 
template  E) truncated 5’Rz RyPS template, F) DNA size marker, G) slow/minimal 
RyPS template, H) RyPS template,  I) ∆5’Rz RyPS template, J) ∆3’Rz RyPS template 
and K) ∆5’∆3’Rz RyPS template. 
 
 
Table 2 and Figure 3.5 give a comparison of the products generated by RyPS 
after in vitro transcription using PCR product as template. The bracketed values 
indicate ribozyme sizes if the 5-base larger template was used to generate RNA. 
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Table 3. 2: Size predictions of the RyPS products produced by cis-cleavage after 
an in vitro transcription using PCR products as template 
 
Product 5’Rz 
[+5] (nt) 
3’ Rz 
(nt) 
shRNA 
(nt) 
5’Rz-
hairpin 
[+5] (nt) 
Hairpin-
3’Rz (nt) 
RyPS 
[+5] 
(nt) 
Fast 
System 
75 [80] 73 69 144 
[149] 
142 217 
[222] 
∆5’Rz 
Knockout 
Absent  73 Absent 143 
[148] 
142 216 
[221] 
∆3’Rz 
Knockout 
75 [80] Absent Absent 144 
[149] 
141 216 
[221] 
∆5’∆3’ 
Knockout 
Absent Absent Absent  Absent  Absent 215 
[220] 
* Values denoted in [] were generated by PCR and are 5 nt larger than the original 
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Figure 3. 5: Schematic 
representation of the RyPS 
products generated during in 
vitro transcription, separated 
by electrophoresis. 
This figure serves to compare 
the differences between the 5’ 
ribozyme when it is generated 
normally by PCR, and when it 
is generated to be 5 bases 
larger. This size difference is 
only seen where the 5’ 
ribozyme is present, thus the 5’ 
ribozyme, 5’ ribozyme + 
shRNA and the entire RNA 
cassette are affected. Red bands 
represent the species with a 5 
base larger 5’ ribozyme, 
whereas black bands indicate 
normal fast RyPS species. 
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The 3’ ribozyme generated from the PCR template is significantly smaller 
than that generated from the restriction digest template. This is seen in Figure 3.6, 
where the 3’ ribozyme appears a few positions above the shRNA. In Figure 3.6, lanes 
A-D, various species of functional and knockout ribozymes are used. Lane B contains 
the 5’ ribozyme knockout, and should only produce a 3’ ribozyme and a 5’ ribozyme-
shRNA conjugate after cleavage. Lane C contains the 3’ ribozyme knockout, and 
would conversely contain a released 5’ ribozyme and 3’-ribozyme-shRNA conjugate. 
Simply by comparing lanes A-C one is able to establish the species of each of the 
bands present by their disappearance and reappearance in each of the respective 
knockouts. The ∆5’ Rz RyPS and ∆3’Rz RyPS do not produce a shRNA fragment, 
thus the only fragment unique to the RyPS lane (Figure 3.6 lane A) is the lowest 
band, which should represent the shRNA species. By a similar process of elimination, 
and comparing lanes B and C in Figure 3.6, one is able to establish that the band 
above the shRNA is the 3’ ribozyme, and the band above that is the 5’ ribozyme. The 
5’ ribozyme identity was confirmed further by comparing it to the species in lanes E-
G, whereby the 5’ ribozyme species are 5 bases bigger, which correlate in size to the 
original ribozymes. These data provide convincing evidence as to the positioning and 
release of the species of RNA generated by RyPS.  
Within the catalytic core, there are 4 nucleotides involved in allowing for the 
co-axial alignment of stems I and II causing the formation of the tertiary structure. 
These nucleotides (5’-C3U4G5A6-3’) were thought to be of a highly conserved nature, 
and any of their removal or alteration results in cleavage abrogation. However in an 
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attempt to generate the 5’ and 3’ ribozyme knockout mutants, the substitution 
reaction 5’-C3U4G5A6-3’→ 5’-C3C4G5A6-3’still resulted in cleavage in an in vitro 
environment (data not shown). Understandably cytosine and uracil are similar in 
structure which possibly allows for the ribozyme to fold into the tertiary 
conformation. Furthermore, Martick and Scott showed that substitution mutations of 
key nucleotides involved in the acid-base reactions within the core still allowed for 
cleavage to occur, albeit less. These types of changes within the ribozyme catalytic 
core were previously shown to prevent ribozyme cleavage, within the minimal 
system. The minimal hammerhead ribozyme was most likely dependent on higher 
concentrations of magnesium, but was also far more sensitive to changes within the 
catalytic core, as they might lead to greater instability of the tertiary structure. It was 
found that deletion of the uracil base prevented any cleavage activity, and is assumed 
that this would occur if any of the bases within the 5’-C3U4G5A6-3’ motif were 
removed, since their role is that of a pivotal and core stabilizing nature, allowing for 
the extreme distortion of the naturally occurring double helix of stem I (Martick and 
Scott 2006). 
On several occasions an RNA ladder was used. However this produced poor 
quality bands, which was not owing to the quality of RNA used, rather the size of the 
gel (41cm) which seemed to cause some of the bands to smudge. 
 
 91
 
 92
Figure 3. 6: An autoradiograph of the RyPS in vitro transcription products, 
using PCR generated templates. 
Lanes A and E both contained the same fast functional RyPS template, however, lane 
E had a primer that increased the size of the 5’ ribozyme template, the transcription 
product visibly larger in comparison. Lanes B and F contained the ∆5’ ribozyme 
knockout clone as template, and a slight increase in the ∆5’ ribozyme + shRNA 
species in lane F can be seen. Lanes C and G contained a ∆3’ ribozyme knockout 
clone, again a size increase witnessed by the 5’ ribozyme. Lastly Lanes D and H 
contained the ∆5’∆3’ ribozyme knockout as a template. From this result one can 
clearly deduce the species presented in the autoradiograph, denoted on the right side. 
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The greatest concern from the data is that the predicted sizes of the RNA 
species do not correlate to those seen on the autoradiograph. The 5’ ribozyme and 3’ 
ribozyme are predicted to be 2-3 bases apart however on the autoradiograph it would 
appear to be more. The shRNA is predicted to be 4 bases smaller than the 3’ 
ribozyme and 6 smaller than the 5’ ribozyme, which again appears to be different 
from the autoradiograph data. Owing to the nature of the system, no leeway can be 
given to the shRNA size or structure. The shRNA is an exact Dicer substrate and any 
alterations or modifications will results in the failure of its recognition, and no 
silencing will occur. Potentially the shRNA is the correct size, and the other 
fragments (5’ and 3’ ribozymes) are larger than anticipated. 
 
 
 
 
 
 
 
 
 
 
 
 
 94
Northern blot analysis of RNA generated by in vitro 
transcriptions 
 
The RyPS has shown to have functional ribozymes in an in vitro environment, 
resulting in the release of 3 individual species. However as indicated by in vitro 
transcription, RyPS cleaves into 3 distinct species with sizes that vary to the intended 
values. Even though no measurement of size was done, the large variance in sizes of 
the cleavage products seen with in vitro transcription experiments led to the 
conclusion that even though the ribozymes had a high level of activity, their target 
site may differ from the intended site. Should RyPS release the shRNA as a 
differently sized species, no RNAi will be induced within the cellular environment. 
Ultimately the best explanation of RyPS activity would be derived from the 
analysis of the products generated within a cellular environment, as that would 
include the various other agents involved in ribozyme cleavage within that 
environment, such as pH, metal ion concentration and innate RNAs and proteins. 
However since the initial in vitro transcription data indicated that RyPS was 
malfunctioning, analysis was initially performed on RNA generated in this manner. 
Isolation and identification of the individual RNA species generated by RyPS, within 
a size defining environment would give possible insight into which RNA species are 
not behaving according to the expected model. Northern blotting allows for the exact 
identification of RNA species, as they can be separated and defined by individual 
nucleotides. Furthermore, probing with a complementary radio-actively labelled 
oligonucleotide provides specific and sensitive detection of the target.  
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A northern blot was performed on the RyPS products generated by in vitro 
transcription, probing for each individual component. Each of the various knockout 
clones were included, which would further substantiate any data obtained from the 
northern blot. 
The RNA was stained with ethidium bromide and viewed under UV trans-
illumination after electrophoresis through a polyacrylamide gel. This step was 
included to validate RNA quality and consistency of RNA concentration. The data 
produced shows all RNA species present, and the various RyPS products are clearly 
visible. Various DNA oligonucleotides were end-labelled to serve as general size 
controls. Even though DNA and RNA have different electrophoretic mobility, they 
can still be compared to give a general indication of sizes present. Figure 3.7 shows 
an ethidium bromide stain of the acrylamide gel containing the in vitro transcription 
RyPS products. 
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   ______________________________________ 
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Figure 3. 7: An ethidium bromide stain of RNA generated by in vitro 
transcription prior to transfer onto a nitrocellulose membrane. 
All RyPS knockout clones are included in lanes A-D. Lane A contains the functional 
RyPS, whereby each individual component of the RyPS is released. It was noted that 
the activity of the 5’ ribozyme is less than expected, due the presence of 5’ ribozyme-
shRNA. The 5’ ribozyme knockout clone in lane B, released only the 3’ ribozyme 
while the 5’ ribozyme and shRNA remained uncleaved. Similarly, lane C contains the 
3’ ribozyme knockout, in which the 5’ ribozyme is released, and the 3’ ribozyme does 
not cleave to release the shRNA. Lane D has both ribozymes knocked out, thus no 
cleavage product is released. RNA species are defined according to comparison of the 
RyPS and respective knockout clones, resulting in the identification of each species 
present by elimination. Lanes E-H are DNA sizes controls, indicated by the blue 
arrows on the right. Below the ethidium bromide stain of the in vitro transcription is a 
schematic illustration of the various species present in the above diagram, providing 
easier recognition.  
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Interestingly, the positioning of the shRNA is far lower than anticipated. 
According to what was expected from cleavage, the shRNA generated was meant to 
be 69 bases in size. In Figure 3.7, the shRNA species lies between 50-62 DNA bases, 
which suggests that the shRNA is somewhat smaller than the intended size. 
Furthermore similarly sized DNA will generally migrate further than its RNA 
counterpart, owing to the lack of the 2’ oxygen. Taking this into consideration, the 
shRNA is far smaller than expected, and is assumed to be in the regions of 50-55 
bases. If proven true, this product is unfit to generate knockdown of its homologous 
target. 
Northern blot analysis confirmed what was deduced from the in vitro 
transcriptions and ethidium bromide stained RNA in Figure 3.7. In the analysis it was 
shown that the shRNA was far smaller that the intended sizes. Furthermore the 3’ 
ribozyme is also smaller than intended, suggesting that the ribozymes are cutting at 
multiple sites. The RNA generated by in vitro transcriptions was probed individually 
for each RyPS species, shRNA, 5’ ribozyme and 3’ ribozyme, depicted in Figure 3.8. 
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Figure 3. 8: Comparison of the three northern blots for the 5’ and 3’ ribozymes 
and the shRNA of RyPS. 
Lanes A-D are functional RyPS, 5’ribozyme knockout RyPS, 3’ ribozyme knockout 
RyPS and 5’3’ ribozyme knockouts, respectively. Data set 1 was probed for 5’ 
ribozyme and is clearly visible in each of the respective lanes. The 5’ ribozyme 
element is present in both the single 5’ ribozyme as well as the uncleaved 5’Rz-
shRNA conjugate.  Some cross-reactively occurred with the 3’ ribozyme, which is 
slightly visible in lanes A and B, and is owing to the potential overlap of the 5’probe 
with the 3’ ribozyme owing to ribozyme similarity. Data set 2 was probed for 
shRNA, present in its processed form as well as any uncleaved products in lanes A-
D. The shRNA was confirmed to be positioned between 50-62 DNA bases, according 
to the DNA oligonucleotide ladder, seen with ethidium bromide staining. Lastly, data 
set 3 probed for 3’ ribozyme, appearing just above the 5’ ribozyme position. Below 
each blot is a diagrammatic representation of the primer binding sites on each of the 
ribozymes and shRNA. Below each blot is a representation of the region in which 
each of the primers bound their respective target. Part of panel 1 is the 5’ ribozyme, 
panel 2 the shRNA and panel 3, the 3’ ribozyme. 
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As expected, the species identified by the northern blot analysis confirmed 
those produced by the ethidium bromide stain when comparing the various knockout 
clones. This confirms that the shRNA generated is by no means what is intended, thus 
is assumed to be unable in producing target knockdown. It would appear that the 5’ 
ribozyme cleaves at the cleavage triplet as expected. However the 3’ ribozyme seems 
smaller than the predicted size of 88 bases, seen positioned just above the 5’ 
ribozyme in Figure 3.8. This would indicate that the 3’ ribozyme processing is 
aberrant, and that the target cleavage sites are not being cut.  
If this is so, it may be useful to determine where the ribozymes are cutting within 
RyPS as this will aid future and corrective design. 
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Cellular Assessment and HBV knockdown 
 
Ultimately, the best measure to determine whether RyPS was functional was 
to place it in an environment where it is expected to induce knockdown of target. The 
cellular environment contains many elements that cannot be accounted for in the in 
vitro environment. Other RNA and proteins species play a role in the formation of 
secondary and tertiary structures. Divalent metal ion concentration is different to that 
of the in vitro environment, and is often at far lower concentrations within the cell, 
too low for the minimal/slow hammerhead ribozymes to function. Magnesium is 
required for the stability and formation of both secondary and tertiary structures of 
the ribozymes, previously also thought to be responsible for the cleavage activity. 
Ideally however, the faster hammerhead ribozymes constructed will be less dependent 
than the minimal species on the presence of magnesium ions for structure 
stabilization, as this is facilitated by the extra-core elements, such as the bulge on 
stem I. 
To assess cleavage functionality knockdown assays were performed, having 
the shRNA target a reporter system. Knockdown was assessed using a dual luciferase 
reporter system. This reporter system utilizes Firefly luciferase and Renilla luciferase 
which are both encoded on one plasmid (psiCheck2.2). A multiple cloning site 
(MCS) is encoded just downstream of the Renilla luciferase gene, before the poly-
adenylation signal. A target sequence from X ORF of HBV was cloned into the MCS, 
and its targeting by a shRNA would result in the knockdown of Renilla luciferase. 
Firefly luciferase is generated off a different expression system (Herpes simplex virus 
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promoter) and is unaffected by the shRNA and serves as an internal background 
control, allowing for uniformity when comparing multiple samples. Figure 3.9 
diagrammatically describes the dual luciferase reporter system.  
 
 
Figure 3. 9: A schematic representation of the region within psiCheck2.2-HBx 
containing the luciferase genes, Renilla luciferase (hRLuc) and Firefly luciferase 
(HFLuc).  
Downstream of hRLuc is a region of the HBx gene, which contains the sites 
recognized by the shRNA released from RyPS (target noted as the blue stripe). Both 
luciferases are generated off different promoter systems. 
 
Pol III promoters are generally used to produce small RNAs. Therapeutically 
these promoters have an advantage of being ubiquitously expressed in all cell types 
and not producing a 5’ cap or 3’ polyadenylation tail, which is ideal for generating 
hairpin molecules such as shRNAs. However, these promoters also have 
therapeutically undesirable properties. A well characterized and commonly used Pol 
III promoter is U6, which induces a high level of expression of its downstream gene, 
and can be expressed from any cell type.  
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Tissue culture studies provided data of the knockdown effect RyPS had on the 
luciferase-linked target. Human embryonic kidneys cells (Hek293) were transfected 
with the reporter system, with potential therapeutic RyPS template and controls, such 
as GFP. Various controls were included in the luciferase assay, such as a control 
hairpin. 
The shRNA generated by RyPS has also been cloned into a U6 expression 
system, whereby the shRNA is generated by a U6 promoter. This construct has been 
previously used, and is known to have a very significant knockdown effect on its 
target (Carmona et al. 2006). The U6-shRNA served as a comparative control, ideally 
the gold standard which the RyPS knockdown was compared to. Thus should shRNA 
release from RyPS be successful, knockdown would be comparable to the U6-driven 
shRNA. All the results are normalized to a positive control which contains only the 
luciferase reporter system and no therapeutic (shRNA) molecules. A control hairpin 
expressed from U6 is also used, targeting the LacZ gene, to control for specific 
activity caused by either the U6 promoter or a shRNA. All the RyPS constructs are 
tested, including the minimal/slow RyPS, previously shown to have little to no 
activity within the cellular environment. It was anticipated that none of the knockout 
controls will be able to induce knockdown. Figure 3.10 compares the relative 
normalized knockdown of all the RyPS clones to the U6-driven shRNA. The data 
from the luciferase knockdown studies indicated that all of the RyPS species were 
unsuccessful in inducing knockdown of their target.  
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Figure 3. 10: Normalised ratio of Renilla:Firefly luciferase assay, using the dual 
luciferase reporter system. 
Firefly luciferase provides a stable background luminescence as a control, while 
knockdown of Renilla luciferase can be directly compared to it. The positive control 
contained no forms of exogenous RNAi molecules, while the control hairpin 
contained a shRNA driven by the U6 promoter targeted against LacZ. This will cause 
no knockdown, as no innate sequences within the cell are similar. U6-shRNA 
produces a shRNA similar to that of RyPS, however, is generated of a U6 promoter. 
The various prefixes denote the following: F – fast ribozyme, S – slow/minimal 
ribozyme and ∆ – knockout mutant of that ribozyme, causing it to be non-functional. 
The shRNA is functional against its target, as noted by U6-shRNA, causing up to 
88% knockdown. No knockdown occurs with the RyPS clone indicating that the fast 
system is not functioning as intended. 
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 The shRNA generated by the U6 promoter system induced 88% knockdown 
against the targeted HBV sequence. This suggests that the shRNA is functional, and 
can induce knockdown of its target effectively (Carmona et al. 2006). The 
slow/minimal RyPS has no functioning within a cellular environment as shown 
previously, and is confirmed by the lack of knockdown seen. This lack of knockdown 
was expected to occur with the all the knockout controls, owing to the inability to 
generate an exact Dicer substrate. The potential shRNA released by RyPS relies on 
the nuclear export protein exportin-5, to be transported into the cytoplasm. This 
interaction is facilitated by the interaction of the two nucleotide 3’ overhang of the 
shRNA. This is absent from both knockout controls, ∆5’Rz RyPS and ∆3’Rz RyPS, 
as both have a ribozyme attached at 5’ or 3’ end, respectively. RyPS is generated by a 
Pol II promoter, and it is plausible that the 5’ cap present on the mRNA strand 
containing RyPS allows for export of that particular strand into the cytoplasm. Thus 
the shRNA portion of ∆5’Rz RyPS and ∆5’∆3’Rz RyPS may be exported into the 
cytoplasm, however being the incorrect substrate would not result in any knockdown. 
The fast RyPS did not produce a significant form of knockdown of its target. It is 
suspected that the RyPS fails to function within a cellular environment, or fails to 
cleavage into the correct products.  
 
 
 
 107
Additional testing of RyPS was done against HBV using pCH-3091, a greater 
than genome length copy, which has the capability for the generation of live HBV 
virus (Nassal 1992). Similar controls and samples were tested as before in the dual 
luciferase assay. An ELISA against the surface antigen of HBV (HBsAg) was 
performed, using the supernatant from transfected cells. This assay was used to 
confirm the results obtained from the luciferase assay. The basis of this experiment 
relies on the direct targeting on viral mRNA and knockdown efficacy is measured by 
a decrease in viral products/particles. Even though the efficacy of this assay is 
measured by monitoring surface antigen knockdown, it is also a reflection of the 
effects of the shRNA against other HBV proteins such as the polymerase. 
The ELISA is a less sensitive assay compared to the luciferase assay, mainly 
owing to the lack of an internal control. Thus the results obtained from the ELISA 
were neither as sensitive nor accurate, however did give a clear indication of the 
similarity of the results obtained from the luciferase assay. Similarly, very poor 
knockdown was generated by all the RyPS clones shown in Figure 3.11. 
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Figure 3. 11: A normalized ELISA against HBsAg of RyPS against live HBV. 
Huh7 cells were transfected with a replication competent HBV plasmid (pCH3091). 
Similar to the luciferase assay, knockdown of HBsAg was assessed to validate RyPS 
efficacy. The positive control contained no forms of exogenous RNAi molecules, 
while the negative control contained a shRNA driven by the U6 promoter targeted 
against LacZ. U6 RyPS hairpin produces a shRNA similar to that of RyPS, however, 
is generated of a U6 promoter. The various prefixes denote the following: S – 
slow/minimal ribozyme, F – fast ribozyme and ∆ – knockout mutant of that 
ribozyme. This data reinforces the lack of activity by the RyPS clone.  
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The data obtained from the HBsAg ELISA share similarities with the previous 
dual luciferase assay, confirming that the knockdown activity from RyPS does not 
occur. The shRNA produced against HBV has a 38% knockdown efficiency. This 
increased value may be owing to multiple factors, including transfection efficiency or 
the cells being swamped with live virus. Most importantly it is noted that the RyPS 
clones produce similar knockdown to the positive control, thus no form of significant 
knockdown did occur. 
The lack of fast RyPS activity could be attributed to several factors, one of the 
more relevant being cleavage activity. It is not known whether RyPS is functional 
within a cellular environment. The original designers of the fast ribozyme within 
RyPS (Saksmerprome et al. 2004) created a chimaeric structure which would be able 
to increase the ribozymes activity in vitro. It was not tested within a cellular 
environment, however is assumed to function owing to the tertiary structure stability 
created by the extra-core elements. A complication in determining the reason for lack 
of RyPS activity is that it is not known if the ribozymes are cleaving in their intended 
sites. If the ribozymes cleave in a site other than the intended, the shRNA released 
cannot induce knockdown of its target, and may explain the lack of knockdown seen 
thus far.  Combining this information, together with that of the in vitro cleavage data, 
it would appear that the incorrectly sized products are being released.  
An important factor that required testing was RyPS activity within a cellular 
environment. This was required for several reasons, as the ribozyme was not a 
naturally occurring species and was a chimaeric structure. The required tertiary 
conformation for cleavage may not be met under cellular concentrations of divalent 
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magnesium ions. Another factor that may be preventing cleavage is that the 
ribozymes were locked within a system with strong secondary structures, particularly 
the shRNA which may affect their functioning. Cellular factors within the cell may 
affect folding, induce compartmentalization or degradation. All these factors may 
play a role in the lack of knockdown by RyPS. Testing the cleavage capabilities of 
RyPS within a cellular environment provided clarity whether the ribozymes were able 
to function. The RyPS was cloned within the dual luciferase system, and by 
monitoring knockdown, assessment was made on the activity of each the ribozymes 
in RyPS. 
 
Assessment of intracellular ribozyme activity 
 
To confirm that the ribozymes found in RyPS are functional within a cellular 
environment, the entire RyPS system was cloned into the MCS of psiCheck2.2, 
immediately downstream of the Renilla luciferase gene. Any ribozyme activity would 
result in the cleavage of the Renilla mRNA, leading to the loss of translational 
functioning. This would cause a decrease in Renilla fluorescence and can be 
compared to a non-cleaved control, ∆5’∆3’Rz RyPS, which kept the mRNA intact. 
This system is described in Figure 2.6, illustrating the basic experimental procedure. 
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Cleavage of the mRNA strand by a ribozyme will cause the transcript to be 
prone to degradation by intracellular RNases. Thus any knockdown observed can be 
accounted for by ribozyme cleavage. Hek293 cells were transfected with each species 
of Renilla luciferase-RyPS, and knockdown of Renilla was assessed after 48 hours. In 
Figure 3.12, the non-cleaving knockout, 5’∆FRz – shRNA – 3’∆FRz (∆5’∆3’Rz 
RyPS) was used as the normalizing non-cleaving control, as it is known that no 
cleavage will occur with that variant, even within in vitro environments which are 
most conducive to ribozyme cleavage. The data indicated that the minimal/slow 
RyPS behaves in a manner similar to ∆5’∆3’Rz RyPS, unable to function within a 
cellular environment. These data, together with the data from the dual luciferase and 
ELISA indicate that the minimal RyPS has no cellular functioning. 
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Figure 3. 12: A normalized ratio of Renilla:Firefly dual luciferase assay, in 
detection of RyPS ribozyme intracellular activity. 
Cleavage activity of any of the ribozymes would result in Renilla luciferase mRNA 
degradation and less fluorescence, as compared to the internal Firefly luciferase 
control. The clone containing 5’∆FRz – shRNA – 3’∆FRz (∆5’∆3’Rz RyPS) was 
used as the normalizing control, since it is known that it is completely non-functional. 
This was followed by a functional RyPS (5’FRz – shRNA – 3’FRz), then the ∆5’Rz 
RyPS (5’∆FRz – shRNA – 3’FRz) both causing greater than 90% knockdown. The 
∆3’Rz RyPS (5’FRz – shRNA – 3’∆FRz) is seen to cause 60% reduction in Renilla 
luciferase. The far right column contained the minimal RyPS system (5’SRz – 
shRNA – 3’SRz), and results in no knockdown of Renilla.  
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The data from Figure 3.12 indicate that all the fast ribozymes function. RyPS 
and ∆5’ ribozyme RyPS share similar knockdown values, indicating that the 
knockdown generated was owing to the activity of the 3’ ribozyme. When cleavage 
was solely dependent on the 5’ ribozyme (∆3’Rz RyPS), 60% was achieved 
indicating that the 5’ ribozyme is less effective at cleavage compared to the 3’ 
ribozyme. The decreased amount of cleavage from the 5’ ribozyme cannot account 
for a complete lack of knockdown in the ELISA and luciferase RyPS-RNAi based 
studies. At 60% functionality some form of knockdown should still be seen, which 
raises two concerns. Initially why is RyPS incapable of causing knockdown of its 
target, and secondly why the 5’ ribozyme has less functionality than its 3’ 
counterpart, as both ribozymes are essentially structurally similar. The data collected 
thus far indicates that RyPS is a catalytically active molecule, however the in vitro 
transcriptions indicated ribozyme cleavage does not occur as anticipated, and is most 
likely cleaving in regions other than the designated cleavage triplets.  
The predicted secondary structure generated from a nucleotide modelling 
engine available online, gave some indication why the 5’ ribozyme only produced 
60% activity in the RyPS-luciferase experiments. 
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Predictive modelling of RyPS secondary structure 
 
Predictive modelling is useful in determining general conformations taken by 
molecules in a set environment. With this information possible monomer-monomer 
interactions can be analyzed, as well as any topological information generated. 
Typically a nucleotide folding program provides information on the possible base 
pairing combinations, as well as the most stable structural forms that are likely to 
occur. mFold (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/rna-
form1.cgi) is a web-based RNA folding program, whereby input of a particular RNA 
sequence allows for the prediction of its multiple secondary structures, arranged in 
accordance to the overall molecule stability, noted by ∆G (Gibbs 1876). The RNA 
sequence of RyPS was analyzed and the most favourable structure to form was 
comparatively similar to that of the intended structure, depicted in Figure 3.13. 
Within the RyPS structure, the component forming the shRNA has taken preference 
to form over that of the ribozymes because of the strong innate hairpin secondary 
structure. It appears that the 3’ ribozyme is structurally unaffected, as stem III 
remains intact, and extra-core elements within stems I and II remain unaffected. The 
data in Figure 3.12 correlated to the activity of the 3’ ribozyme as the predictive 
modelling suggested. However, modelling also predicted that the 5’ ribozyme 
structure was affected by the secondary structure of the shRNA, and this led to stem I 
on the 5’ ribozyme not forming the 5’-UAA-3’ bulge required for enhanced cleavage 
activity. Not all activity ribozyme was lost, suggesting that the 5’ ribozyme had a 
form of stabilized tertiary structure, albeit weaker and was not as effective in 
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maintaining a tertiary structure required for cleavage. The two proposed secondary 
structures are schematically drawn in Figure 3.13., both comparing the differences 
caused by the shRNA of the intended structure and the predicted structure. 
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Figure 3. 13: Intended and predicted structures of RyPS. 
The original ideal structure for RyPS is shown by A, however when analysed with 
RNA folding software, it was found that B had a preference of forming. A mis-
formed region in B is highlighted in green (UAA), which is known to increase the 
cleavage efficiency of the ribozyme. The blue region contains the nucleotides that 
form the shRNA, the black nucleotides indicate the flanking ribozymes (5’ ribozyme 
on the left, 3’ ribozyme on the right), and the red nucleotides indicate the cleavage 
triplets (GUC) on each of the ribozymes.  
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The stabilization of the hairpin disrupted one of the most crucial elements 
required by the 5’ ribozyme for its enhanced functioning. This could most likely 
account for the 60% cleavage efficiency when ∆3’ ribozyme RyPS was cloned into 
psiCheck2.2 (Figure 3.12). This disruption is not completely inhibitory of cleavage, 
and the 5’ ribozyme still maintains cleavage activity, albeit less. This is thought to 
occur as a result of the dynamic nature of RNA which is by no means a static 
structure, and is structurally dynamic. At any one instant the favourable cleavage 
conformation may occur, which will allow for the activity of the 5’ ribozyme. 
Furthermore, the three nucleotides responsible for the bulge may still provide a basis 
for tertiary structure stabilisation however, a less stable system forms.  
Data taken from the previous experiments indicated that RyPS had cleavage 
activity within an in vitro and cellular environment. However, as indicated by the in 
vitro transcriptions data RyPS behaved in an unexpected manner, generating products 
incapable of performing their intended function. The following set of data gave a 
clear indication of the species produced during in vitro transcriptions, which 
suggested that the unintended malformation of the 5’ ribozyme had little effect on the 
products produced from ribozyme cleavage.  
Topography of the template as well as the product may have an influence on 
the functioning of T7 polymerase which is responsible for RNA generation in all the 
in vitro transcription reactions. Small loops and sequence motifs are known to 
influence polymerases, such as additional start and stops sites, or binding motifs, 
however, this is an unlikely cause to the truncations of the RyPS products. When 
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tested in cell culture, human polymerases are also unable to transcribe a product 
capable of inducing target knockdown, suggesting that a similar product is being 
formed either using a T7 bacterial promoter or the mammalian CMV promoter. 
 
Determination of RyPS cleavage sites: Primer extension 
reactions   
 
It was established that the shRNA produced was not what was intended and 
was far smaller than expected. There are only two factors which could play a role in 
the generation of the shRNA. The first was the 5’ ribozyme, which according to size 
correlations appeared to be correctly sized. The second was the 3’ ribozyme, and 
from size comparisons appeared to be smaller than the predicted size. These data 
indicate that one of the ribozymes (or both) is responsible for generating products 
unfit for inducing the RNAi response. Establishing the site of cleavage would 
confirm that aberrant cleavage has taken place and would provide some explanation 
to mechanism of the RyPS cleavage and perhaps explain the mis-cleavage results 
obtained. Primer extension reactions can provide accurate information as to where a 
target oligonucleotide starts. To clarify the exact site of cleavage, a concurrent 
sequencing reaction was performed, in which sequencing information directly 
correlated to the primer extension data owing to the common start primer used. 
A primer extension reaction was performed on non radioactive RNA 
generated by in vitro transcription. Radio isotope-labelled DNA primers were 
designed to bind downstream of the 5’ and 3’ ribozyme cleavage sites, and when 
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subjected to reverse transcription the primer would be extended until the polymerase 
falls off the RNA template. A sequencing reaction was performed using the same 
primers, on a DNA template (plasmid origin). Thus for every base added in the 
sequencing reaction, it is matched by the reverse transcription reaction. Therefore, at 
the point where the reverse transcriptase falls off the template RNA, these data would 
correlate to the base at which cleavage occurred on the sequencing control. Figure 
2.10 explains the overall methodology used to determine the cleavage sites of RyPS. 
The 5’ ribozyme cleavage site was analyzed by having the probe bind to the 
shRNA. This would have extended to the start of the shRNA molecule, and would 
indicate the end of the 5’ ribozyme (and hence the cleavage site). Figure 3.14 depicts 
that the primer extension data showed that the 5’ ribozyme was able to successfully 
form a structure capable of cleaving at the desired cleavage triplet. Thus it is assumed 
that the 5’ ribozyme in any of the in vitro data sets is the correct size (75 bases).  This 
occurs despite the bulge on stem I not forming correctly, suggesting that the 5’ 
ribozyme retains some form of correct cleavage activity. 
Analysis of the cleavage data of the 3’ ribozyme showed that cleavage did not 
occur at the desired triplet, and did so at another site downstream of the proposed 
cleavage triplet illustrated in Figure 3.14. The exact site of cleavage cannot be 
confirmed, however is estimated to occur just before the UAA bulge motif of stem I. 
For this to occur, the 3’ ribozyme would have to fold into a structure capable of fully 
supporting the highly conserved cleavage pocket, as well as provide some form of 
stability required during cleavage. Predictive RNA folding has shown that it is 
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unlikely for any form of structure to be produced in order to allow for cleavage as 
proposed by the primer extension data.  
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Figure 3. 14: Primer extension reactions together with sequencing data indicate 
the region of cleavage caused by each of the ribozymes. 
Lanes G, A, T and C provide sequencing data of the regions around the 5’ and 3’ 
ribozyme cleavage triplet. In panel 1, Lane P contains the primer extension product, 
and its termination correlates to after the GTC cleavage triplet of the 5’ ribozyme. In 
Panel 2, the primer extension reaction (Lane P) accompanied with sequencing data 
indicate the region of cleavage within stem I of the 3’ ribozyme, downstream of the 
predicted ribozyme cleavage site, indicative of aberrant cleavage. Below each 
respective panel is a mapped site of both the 5’ and 3 ribozymes. The 5’ ribozyme is 
mapped to cleave after the GUC cleavage triplet. The 3’ ribozyme is mapped to 
cleave within stem I, near the 5’-UAA-3’ bulge.  
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It would appear that the 5’ ribozyme cleaves in the predicted region, releasing 
the shRNA at the correct point. The 3’ ribozyme however does not cleave at the 
correct site, and would produce a hairpin larger than expected. This does not correlate 
with the data previously shown in the northern blots, thus it is thought that the 3’ 
ribozyme cleaves in multiple regions of the RyPS. The event of additional processing 
may be the most likely cause of the smaller RyPS products. It is assumed that the 5’ 
ribozyme is unaffected by potential additional processing, confirmed by both the 
primer extension reactions and northern blots and it is seen that the 5’ ribozyme is of 
the predicted size. However it is found that the shRNA generated is far smaller than 
what is required and expected, and cannot possibly function as an RNAi molecule. 
The dilemma occurs because the 3’ ribozyme, if processing further up stream into the 
shRNA, should be far larger than it appears on the northern blot. The 3’ ribozyme 
appears smaller than its expected size (88 bases), and is a similar size to the 5’ 
ribozyme (approximately 78 bases). This would indicate that a form of additional 
processing is occurring by the ribozymes, or that the polymerase is prematurely 
releasing from the DNA template, hence the additional bands seen around the 3’ 
ribozymes after in vitro transcriptions (results Figure 3.3 and 3.6). It is unclear 
whether the components of RyPS would have a propensity bind to each other, as 
secondary structure analysis shows little extra interaction between the ribozymes and 
short hairpin. Searching for potential binding sites with complementary sequence 
alignment tools has yielded no results either. It is postulated however, that it only 
requires a cleavage triplet NUH (possibly even NHH) and enough stable binding in 
stems I and III to allow for tertiary structure stability, and cleavage could occur. This 
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event may occur on the shRNA, allowing the antisense strand to be cleaved, which is 
unlikely, and the stability of the shRNA would not allow for partial binding by any of 
the ribozymes. 
 
Ultimately it is unknown which ribozyme causes the additional cleavage of 
the shRNA, however further investigation may shed some light on the matter. Using 
the primer extension reaction, and using a series of primers that tile upstream from 
the 3’ ribozyme, one should be able to determine whether the 3’ ribozyme be 
truncated in any manner.  It is thought that the 5’ ribozyme is not responsible for the 
decreased size of the 3’ ribozyme, because when it is knocked-out in control clones, a 
similar 3’ ribozyme product forms in comparison to the functional RyPS (Figure 3.6), 
thus factors other than the 5’ ribozyme are responsible for its truncation. It is not 
known which ribozyme is involved in the truncation of the shRNA.  
 
The cleavage triplet in hammerhead ribozymes which allows for the greatest 
rate of cleavage has been defined as NUH, which is present in multiple forms around 
the stem I bulge, and could provide a putative cleavage site. Some groups have 
broadened this definition to NHH, which greatly increases the potential cleavage sites 
around the bulge on stem one of the 3’ ribozyme. However cleavage at that point is 
very unlikely to occur, owing to the fact that the ribozyme structure is too unstable to 
utilize any of the nucleotides around the bulge as a cleavage site. Should cleavage 
occur as predicted by the primer extensions, the RyPS products would have the 
following sizes: 5’ ribozyme - 75 nucleotides, shRNA - 87 (69 + 18) nucleotides and 
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3’ ribozyme - 70 (88 – 18) nucleotides. This is known not to be true, as the northern 
blot studies have proven otherwise (first demonstrated by the ethidium bromide stain 
of RyPS and the knockout clones prior to blotting). The cleavage site indicated by the 
primer extension is thought to be incorrect, as no other 3’ ribozyme products support 
this data in the northern blot analysis. The product produced during 3’ ribozyme 
primer extension is most likely an artefact of the reaction, or is the result of additional 
processing performed by either the 5’ ribozyme or 3’ ribozyme. 
One concern was the lack of adherence of the cleavage products to the 
predicted sizes. RNA ladders were tried with little success, often resulting in double 
and faint bands, unrelated to the condition of the RNA. Thus the analysis of the 
knockout mutants gave an indication of which products are present in the 
autoradiograph. In both autoradiograph figures, it is seen that the expected size of the 
hairpin (69), the 5’ribozyme (75) and 3’ ribozyme (88) were not observed, and that 
one of the products (or both potentially) are differently sized. There are myriad 
possibilities as to why the RyPS system does not function as expected, the most 
feasible being structure and additional processing. It is known that both the 5’ and 3’ 
ribozymes are functional within a cellular environment (up to 90%), as seen using 
RyPS downstream of Renilla luciferase in Figure 3.12 in the results section. RyPS 
ribozyme cleavage is highly active within the cellular environment, demonstrating 
that the faster ribozymes cleave within that environment. As expected the slow RyPS 
is unable to induce knockdown of Renilla, indicating that those minimal ribozymes 
do not function within the cellular environment.  
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Disruption of the bulge on stem I has its effect on ribozyme cleavage. This 
disruption was first noticed in secondary structure analysis using the internet based 
program m-fold. In this it was predicted that the shRNA within the structure takes 
preference in forming, causing a shorter stem I of the 5’ ribozyme (Figure 3.13). This 
disrupts the bulge on stem I, which is responsible for the tertiary structure 
stabilization, and is assumed to be responsible for decreased cleavage. This was 
shown by the 3’ ribozyme RyPS knockout, whereby cleavage of the Renilla luciferase 
mRNA was solely dependent on the 5’ ribozyme, which had a mis-formed bulge on 
stem I. Furthermore is it assumed that it is a requirement for extra-core elements to be 
stable in structure, allowing for an increase in cleavage. 
It is speculated that an additional cleavage reaction is taking place on the 
shRNA, as it is far smaller than the originally predicted size of 69 bases. Furthermore 
the 3’ ribozyme is smaller than anticipated (< 88 bases) in the region of 8-10 bases. It 
is unknown what the causes are to these truncated products. One may suggest that 
additional cleavage is occurring, whereby the ribozymes are able to recognize 
additional elements other than the predicted cleavage site, and are able to form the 
tertiary structures required for cleavage to occur. Alternatively, the plasmid template 
may have become truncated during the cloning process. This is owing to the high 
frequency of secondary structure in the DNA and is known not to be found 
favourable in bacterial genomes, and is often excised, however this is unlikely as the 
knockout clones are able to generate similar products to the functional RyPS.  
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Ultimately, cleavage is sequence dependent, and a change of shRNA within 
the cassette will provide a different sequence and may prevent its truncation. 
Sequence complementarity between the ribozymes and certain sections of the shRNA 
will need to be avoided, to prevent any unintended cleavage occurring. One may also 
consider revising the hammerhead ribozymes used. The ribozymes used in RyPS are 
an adaptation of the peach latent mosaic viroid (PLMVd) hammerhead ribozyme, and 
a more naturally occurring ribozyme may provide a better predictable cleavage, since 
it has to function naturally without compromising viral replication. In addition to 
ribozyme exchange, disruption of the bulges on stem I should be avoided, caused by 
the secondary structure of the shRNA.  
One potential means of overcoming the disruption of the bulge on stem I, is to 
make it independent of binding to the shRNA. This was done using ribozyme derived 
from satellite tobacco ringspot virus (sTRSV) by Nelson et al. 2005. They created a 
hammerhead ribozyme with a looped stem I, which is independent from other 
ribozyme elements. If incorporated into the RyPS system, a diagrammatic 
representation of the secondary structure is shown in Figure 3.15.  
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Figure 3. 15: A schematic representation of the possible adaptation to the 
currently used ribozymes in RyPS. 
This new version avoids disruption of extra core elements, by the shRNA, allowing 
for the formation of the loop I loop II kissing interaction. 
 
RyPS usage extends beyond HBV treatment to the treatment of other diseases 
including cancer, viruses and autosomal diseases. Another benefit of the system is 
synthetic RNA production, which would require the replicative properties of T7 
polymerase, which is also far cheaper to produce than the current methods employed 
for this. However, the greatest benefit of RyPS is the tissue-specific inducible 
expression of a shRNA. Pol II promoters will allow for the systemic delivery of 
RyPS, however will only be effective in targeted tissues. The level of expression of 
RyPS can be controlled and regulated, as it is unnecessary to mass produce RNAi 
therapeutic molecules intracellularly, and as shown by some groups has led to cell 
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death. Furthermore, RyPS offers the potential to be expressed from a single Pol II 
promoter as a concatemer of RyPS sequences, all containing various shRNA 
molecules, decreasing the chance for escape mutants developing. Ultimately RyPS 
requires further thorough analysis of potential intra- and inter-binding activity, 
typically in the form of various hammerhead ribozyme species, shRNA species and 
combinations of both. Understanding that as little cross reactivity must occur between 
individual RyPS components will help lessen the occurrence of unintended cleavage 
products. If this can be accomplished, RyPS stands great potential to be developed 
into a therapeutic molecule for use in countries that can no longer depend on 
expensive unstable drugs. 
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Appendices 
Appendix 1 
 
 
 
Figure A1: The multiple cloning site (MCS) is shown, flanked by the M13F/R sites. Restriction sites are unique within the MCS 
and are cut by enzymes shown in blue. DNA fragment insertion occurs at the Eco32I site during T/A cloning. This figure is taken 
from the user notes on pTZ57R. 
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Appendix 2 
 
6x Agarose DNA Loading Dye 
0.03% (w/v) Xylene cyanol FF 
0.015% (w/v) Orange G 
60% Glycerol 
60 mM EDTA 
 
Boric Acid Buffer for electrophoresis 
10 mM Sodium hydroxide 
pH to 8.5 with boric acid 
 
Ethidium bromide stock (100 x) 
100 mg EtBr dissolved in 10 ml distilled water, stored at room temperature. 
 
LB broth and plates supplemented with ampicillin 
10 g Bacto-Tryptone 
5 g Bacto-Yeast Extract 
5 g Sodium Chloride 
1 ml 1000x ampicillin stock 
Up to 1 L distilled water 
To make agar plates, add 12 g agar 
 
Ampicillin stock (1000x) 
50% (w/v) Ampicillin 
50% (v/v) distilled water 
50% (v/v) ethanol 
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IPTG and X-Gal stocks 
200 mg IPTG per 1ml distilled water 
20 mg X-Gal per1ml dimethyl formamide 
 
10x TBE buffer (pH 8) 
0.685 M Tris-HCl 
0.8895 M Boric Acid 
0.02 M EDTA 
 
Denaturing polyacrylamide gel (10%) 
8 M Urea 
0.5% (w/v) Bis-acrylamide 
9.5% (w/v) Acrylamide 
1x TBE 
0.05% (v/v) TEMED 
0.5% (v/v) Ammonium persulphate stock 
 
Ammonium persulphate (APS) stock 
100 mg APS in 1 ml distilled water 
 
Phosphate-buffered saline  
0.21 g KH2PO4 
9 g NaCl 
0.726 g Na2HPO4.7H2O 
Made up to 1 L and autoclaved 
 
RNase free water 
1 ml DEPC in 1 L of water 
Incubate overnight at 37oC and autoclave the following day. 
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Appendix 3 
 
It should be noted that any reactions involving the use/generation of RNA should be 
done as RNase free as possible. The environment one generally works in contains a 
variety of species of RNases, particularly those shed by humans. RNases are 
generally difficult to get rid of, and special precautions need to be taken to ensure the 
best quality RNA is produced. Gloves should be worn at all times, ensuring that they 
are sprayed with 70% ethanol intermittently, as well as an RNase degrading soap 
(such as RNase-Away). Instruments such as glass wear and spatulas should be 
washed with 1% SDS solution and rinsed with DEPC treated water, covered in foil 
and a standard autoclave procedure performed. All surfaces should be cleaned with an 
RNase degrading substance (1% SDS solution can be used). It is advisable to wear a 
face mask, to prevent aerosols entering the reaction environment. Any components to 
a reaction should be RNase free, including the water used and any chemical added. It 
is suggested to use chemicals separated from general lab use. Any large volumes of 
water that need to be used (such as water used for buffers) should be treated with 
DEPC first. 
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